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SUMMARY 
 
 
 
Human embryonic stem cells (hESCs), derived from the inner cell 
mass of the blastocyst, are pluripotent and can differentiate into any tissue 
from the 3 germ layers. At the same time, these cells can proliferate 
indefinitely in vitro in the undifferentiated state under appropriate conditions. 
In recent years, stem cells have gained prominence because they potentially 
can be a source for replacement of cells and tissues that have been damaged 
in the course of disease, infection, trauma or congenital abnormalities. 
Despite the immense potential hESCs hold for regenerative medicine, 
one of the most pertinent concerns using differentiated cells from hESCs is 
the presence of residual undifferentiated cells, which carry the risk of teratoma 
formation. Numerous studies have shown that undifferentiated hESCs can 
form teratomas in SCID mouse models. Furthermore, because the 
differentiation process is not 100% efficient, residual hESCs may remain in 
the differentiated cell product 
To produce therapeutically useful cells, we need to characterize and 
understand hESCs through the identification of cellular components and 
pathways that govern their proliferation and differentiation. One of the ways to 
identify the receptors or antigens involved in hESC regulation is to utilize 
antibodies against hESC surface markers. Routinely, hESCs are 
characterized using antibodies targeting cell surface markers such as stage-
specific embryonic antigen (SSEA-3 and -4), TRA-1-60 and TRA-1-81. 
However, these antibodies are not unique to hESCs as they were raised 
against 4- to 8-cell stage mouse embryos or embryonal carcinomas (EC). 
 VIII 
Consequently, our group generated a panel of monoclonal antibodies (mAbs) 
targeting cell surface markers on undifferentiated hESCs by immunizing mice 
with intact live hESCs as the immunogen. These mAbs can potentially be 
used in the following ways: 
 (1) To discover novel hESC surface markers, 
 (2) To characterize the hESC populations and 
 (3) To separate the undifferentiated cells from the differentiated cells. 
One of the antibodies from the panel, mAb 84 which is an IgM, is a novel 
cytotoxic monoclonal antibody, which selectively kills undifferentiated 
pluripotent stem cells (hESC and iPS cells) and not differentiated cells within 
45 min of incubation in vitro.   
By mass spectrometry, the antigen target of mAb 84 was identified as 
podocalyxin-like protein-1 precursor (PODXL), a highly glycosylated 
sialomucin with an apparent molecular weight of ~ 200 kDa. mAb 84 killing of 
hESCs was found to be independent of complement and temperature but was 
dependent on incubation time and concentration of antibody used. Upon 
incubation of hESCs with other antibodies to PODXL, we found that though all 
the mAbs bind to hESCs, only mAb 84 was cytotoxic. In addition, it was 
determined that mAb 84 binds to O-linked glycans on PODXL. 
In SCID (Severe Combined Immunodeficiency) mice models, we 
showed that teratoma formation by hESCs in vivo was eliminated following 
treatment with mAb 84. This is compared to untreated cells which formed 
teratomas after 6-9 weeks post-injection. Concommitantly, when 
undifferentiated hESCs were treated with other hESC-specific mAbs from our 
panel in vitro and injected into SCID mice, teratomas formed as early as 7 
 IX 
weeks post-injection. These results suggest that the cytotoxic properties of 
mAb 84 on hESCs are epitope specific and not based only on binding to 
PODXL or to any surface antigens on hESCs. Preliminary studies also 
showed that treatment of spontaneously differentiating cells with mAb 84 was 
able to significantly delay the onset of tumor formation. 
Mechanistically, treatment of hESCs with mAb 84 did not induce 
apoptosis because elevation of caspase activity and DNA fragmentation was 
not observed. Instead mAb 84 kills hESCs via a process similar to oncosis. 
Cell death was preceded by cell aggregation and examination of the cell 
surface by scanning electron microscopy (SEM) revealed the presence of 
pores and the aggregation of PODXL after mAb 84 treatment. Additionally, we 
hypothesize that the pore formation on the cell surface membrane was a 
consequence of the degradation of several cytoskeleton-associated proteins 
within 10 min of mAb treatment. 
This is the first study on antibody-mediated oncosis which utilizes 
hESCs as a model. The significance of these findings is that this antibody can 
be used to eliminate contaminating hESCs and iPS cells from the 
differentiated cell population prior to clinical applications because teratoma 
formation in vivo would severely compromise the success of the transplant. 
This “clean-up” step prior to transplantation will increase the safety of this 
procedure and alleviate concerns over the use of hESCs and iPS cells as the 
starting cell population for cell therapy.   
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 1
CHAPTER 1 INTRODUCTION 
 
1.1  Background 
Human embryonic stem cells (hESCs) hold immense potential for 
regenerative medicine as they possess the dual properties of proliferating 
indefinitely and differentiating into cell types representing the 3 germ layers 
[1,2]. Studies have demonstrated that these cells can be differentiated to 
lineage-specific cell types, such as cardiomyocytes [3,4], insulin-producing 
cells [5-7], and neural–like cells [8-10]. However, there are several problems 
and safety concerns associated with the use of hESCs for cell-based 
therapies [1,11]. Firstly, hESCs have to be reproducibly differentiated into the 
specific cell types under a controlled environment. Subsequently, as the 
differentiation process is not 100% efficient, the cell type of interest has to be 
separated from residual cells prior to transplantation that are partially 
differentiated or remain undifferentiated. In the latter situation, the presence of 
residual undifferentiated hESCs in the transplant can potentially result in 
teratoma formation in vivo [1,11-13].  
To produce therapeutically useful cells, we need to characterize and 
understand hESCs through the identification of cellular components and 
pathways that govern their proliferation and differentiation [14,15]. One of the 
ways to identify the receptors or antigens involved in hESC regulation is to 
utilize antibodies against hESC surface markers. Routinely, hESC are 
characterized using antibodies targeting cell surface markers such as stage-
specific embryonic antigen (SSEA-3 and -4), TRA-1-60 and TRA-1-81. 
However, these antibodies are not unique to hESCs as they were raised 
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against 4- to 8-cell stage mouse embryos or embryonal carcinomas (EC) 
[16,17]. Consequently, our group generated a panel of monoclonal antibodies 
(mAbs) targeting cell surface markers on undifferentiated hESCs by 
immunizing mice with intact live hESCs as the immunogen. These mAbs can 
potentially be used in the following ways: 
 (1) To discover novel hESC surface markers, 
 (2) To characterize the hESC populations and 
 (3) To separate the undifferentiated cells from the differentiated cells. 
One of the antibodies from the panel, mAb 84 which is an IgM, was 
found not only to bind but also kill undifferentiated hESCs. The ability of mAb 
84 to selectively kill undifferentiated hESCs is extremely beneficial as mAb 84 
can potentially be used to remove residual undifferentiated hESCs from 
differentiated cells prior to therapeutic applications. 
 
1.2 Thesis Objective 
As mentioned above, our group previously generated a panel of mAbs 
targeting cell surface markers on undifferentiated hESCs. From this panel of 
antibodies, mAb 84 which is an IgM, was identified to bind and kill 
undifferentiated hESC.  
Having identified mAb 84 as a potentially good candidate to eliminate 
undifferentiated hESCs, further characterization of mAb 84 is essential before 
it can be effectively used. The objective of the research for this thesis is 
therefore to further define mAb 84 in the following areas: 
(1) In vitro characterization of mAb 84, 
 (2) In vivo characterization of mAb 84 and, 
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 (3) Elucidation of death mechanism of mAb 84. 
 
1.2.1 In vitro characterization of mAb 84 
First, the identity of the antigen target on hESCs will be identified 
through immuno-precipitation with mAb 84 followed by mass spectrometry 
analysis. Subsequently, other antibodies to the identified antigen will be tested 
to determine if these other antibodies are also cytotoxic to undifferentiated 
hESC. Work will also be carried out to investigate the effect of complement, 
temperature and concentration of antibody used on the cytotoxicity of mAb 84 
on hESCs. The kinetics of mAb 84 killing on hESCs will also be studied. The 
specificity of mAb 84 will be assessed by comparing the binding and 
cytotoxicity of mAb 84 on undifferentiated hESCs and spontaneously 
differentiated hESCs either cultured in the absence of FGF-2 or as hESC-
derived embryoid bodies (EBs). We will also proceed to investigate if the 
binding of mAb 84 to the identified antigen is dependent on post-translational 
modifications, namely; N-linked and O-linked glycosylation. Lastly, we will 
determine if mAb 84 is also cytotoxic to iPS cells.  
 
1.2.2 In vivo characterization of mAb 84 
Here, we will investigate if treatment of undifferentiated hESCs with 
mAb 84 in vitro will eliminate its ability to form teratomas in vivo. Other mAbs 
in our panel will also be compared to determine if the specificity to eliminate 
teratoma formation in vivo is unique to mAb 84. Apart from homogenous 
populations of hESCs, mixed cell populations of differentiated and 
undifferentiated hESCs generated either by differentiating hESCs into 5 day 
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EBs or culturing hESCs without FGF-2 for 12 days will also be evaluated for 
tumor formation and susceptibility to mAb 84.  
 
1.2.3 Elucidation of death mechanism of mAb 84 
 The mechanism responsible for hESC-killing by mAb 84 will be 
elucidated. Briefly, we will determine if mAb 84 kills hESCs via apoptosis or 
oncosis and the hallmarks of cell death. Subsequently, the events that occur 
in mAb 84-mediated killing of hESCs will be identified. 
 
1.3 Thesis Organization 
The thesis comprises of seven chapters. 
Chapter 1 describes the background and objectives of this research.  
Chapter 2 is a review of literature and focuses on 4 main areas: (1) the 
importance of hESCs, (2) the concerns and safety issues of using hESC-
derived cell products, (3) the various antibodies that induce cell death and (4) 
the different modes of cell death, namely; apoptosis and oncosis.  
Chapter 3 details the materials and methods of the various 
experiments performed in this thesis.  
Chapter 4 presents results on the characterization of mAb 84 in vitro. 
The antigen target of mAb 84 was identified as PODXL. The cytotoxicity of 
mAb 84 was independent of complement and temperature but dependent on 
incubation time and concentration of antibody used. Results also showed that 
mAb 84 killed iPS cells. 
Chapter 5 presents data on the characterization of mAb 84 in vivo. The 
data showed that SCID mice injected with mAb 84-treated hESCs failed to 
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form teratomas compared to the untreated control or hESCs treated with other 
antibodies, where teratomas were observed after 7 weeks post-injection. 
Chapter 6 elucidates the mechanism responsible for mAb 84 killing of 
hESC. Mechanistically, mAb 84 kills hESCs via oncosis. 
Chapter 7 summarizes the results and conclusions of the thesis and 
discusses the possible directions and future work to be conducted.  
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CHAPTER 2 LITERATURE REVIEW 
 
2.1  Origin and Application of Human Embryonic Stem Cells  
Human embryonic stem cells (hESCs), derived from the inner cell 
mass of the blastocyst, are pluripotent stem cells and can potentially 
differentiate into any tissue representative of the 3 germ layers (Figure 2.1) 
[1,2,14,18]. At the same time, these cells can proliferate indefinitely in vitro in 
the undifferentiated state under the appropriate conditions [19,20]. In recent 
years, stem cells have come into prominence due to their abilities to 
proliferate and differentiate into specialized cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Origin of hESCs and their cell fate. Human embryonic stem cells are derived 
from the inner cell mass of the blastocyst. These cells have the capacity to differentiate into 
the three germ layers, namely; endoderm, mesoderm and ectoderm. 
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Potentially, stem cells may be a source of replacement for cells and 
tissues that have been damaged in the course of disease, infection or causes 
due to congenital abnormalities [1,2,14,18]. Studies by various groups have 
shown that hESCs can be differentiated into various cell types with the goal of 
using these hESC derivatives in transplantation to replace cells that have 
been terminated or crippled by diseases such as chronic heart disease, 
diabetes and Parkinson’s disease. Some examples include cardiomyocytes, 
insulin-producing cells and neurons. He et. al. and Snir et. al. were able to 
reproducibly differentiate hESCs into cardiomyocytes [3,4] and these cells 
exhibited cardio-like characteristics such as action potential and ultra-
structural maturation. Studies by D’Amour et. al. demonstrated that hESCs 
can be differentiated into insulin-expressing cells with an insulin content 
approaching that of adult islets [6]. Although their results were preliminary, 
these findings are critical steps for the development of a renewable source of 
cells for the treatment of diabetes. Several groups have also successfully 
differentiated hESCs into neurons with the aim of using these hESC-derived 
neurons for the treatment of neurological disorders [8-10]. Recently, Geron 
proceeded with the first human clinical trial using hESC-derived cells 
(http://www.geron.com) [21]. The therapeutic product, GRNOPC1, contains 
hESC–derived oligodendrocyte progenitor cells that have demonstrated 
remyelinating and nerve growth-stimulating properties leading to restoration of 
function in animal models with acute spinal cord injury [21,22]. Work is also 
being carried out to evaluate GRNOPC1 in various neuronal diseases such as 
Alzheimer’s disease and Multiple Sclerosis. 
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 These various studies using hESC-derivatives and Geron’s clinical trial 
with GRNOPC1 highlight the immense potential of hESCs for regenerative 
therapy. However, numerous studies have shown that there are safety issues 
associated with the use of hESCs for cell-base therapies [1,11]. These safety 
concerns will be discussed in the following section. 
More recently, an alternative source of pluripotent stem cells was 
reported by Takahashi et. al. and Yu et. al. [23,24]. Known as induced 
pluripotent stem (iPS) cells, these cells have the potential to proliferate 
indefinitely in culture and still retain their capacity for differentiation into a wide 
variety of cells [23,24]. Human fibroblasts are reprogrammed to iPS cells by 
transient over-expression of a small number of transcription factors [23,24]. In 
addition, these iPS cells have been shown to be comparable to hESCs in 
morphology, pluripotent marker expression and differentiation potential, 
including teratoma formation [23-27]. The derivation of iPS cells can 
potentially overcome two important obstacles associated with the use of 
hESC: immune rejection after transplantation and ethical concerns regarding 
the use of human embryos [25,26]. Like hESC, the presence of residual 
undifferentiated iPS cells in transplants can potentially result in teratoma 
formation in vivo. 
 
2.2 Safety Concerns with hESC-based Therapies 
 Despite the immense potential hESCs hold for regenerative medicine, 
there remain safety concerns associated with the presence of residual hESCs 
in the differentiated cell product. Numerous studies have shown that 
undifferentiated hESCs can form teratomas in SCID mouse models 
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[1,2,13,19,20,28,29]. A study carried out by Hentze et. al. has shown that as 
few as 245 undifferentiated hESCs is sufficient for teratoma formation in SCID 
mice [12].  
During differentiation, because the process is not 100% efficient, 
residual hESCs may remain in the differentiated cell product. In cell-based 
therapies utilizing hESC-derivatives, these residual hESCs contaminants 
could result in the formation of teratomas post transplant or grafting 
[1,11,21,30]. A study by Fujikawa et. al. showed that ES cell-derived insulin-
expressing cells, when transplanted into SCID mice, formed teratomas 
leading to the failure of treatment for Type I diabetes [30]. In Geron’s clinical 
trial with GRNOPC1, the process was placed on clinical hold after microscopic 
cysts were observed in animals post treatment 
(http://www.geron.com/GRNOPC1Trial/grnopc1-sec3.html). The presence of 
these cysts in the animals transplanted with GRNOPC1 caused much concern 
especially the possibility of teratoma formation [21]. In a prominent case 
study, a group of Israeli researchers reported that a boy with ataxia 
telangiectasia who had received several fetal neural stem cell transplants 
developed tumors in his brain and spinal cord four years after treatment 
[21,31]. This case study highlights the possibility of tumor formation not just 
from embryonic stem cells but also from other sources of stem cells (including 
fetal neural stem cells)  and may prove to be a major stumbling block for cell-
based therapies.  
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2.3 Solutions to Remove Residual hESCs from hESC-derivatives 
 As mentioned, hESCs exhibit potentially unlimited proliferation capacity 
combined with pluripotent differentiation capacity thus making them an 
attractive source of material for cell therapy applications [1,2,11]. One 
prerequisite for use in cell therapy is the enrichment of the desired cell type 
from unwanted lineages and the removal of potentially tumorigenic cells 
[1,11]. In a review by Hentze et. al., the various methods to eliminate 
unwanted cells and enrich for the desired cell type were summarized (Figure 
2.2) [11]. One of the methods proposed is the use of specific antibodies to 
positively or negatively enrich for the desired cell population. An alternate 
method is to use of cytotoxic antibodies to directly kill residual undifferentiated 
hESCs. The following section provides examples on the use of cytotoxic 
antibodies to eliminate the respective target cells. 
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Figure 2.2 Various methods to eliminate unwanted cells and enrich for desired cell 
type. 
 
 
 
2.4 Use of Cytotoxic Antibodies to Eliminate Target Cells  
 The use of various cytotoxic antibodies to eliminate target cells has 
been reported in many studies. The mAb, MEM-59, recognizes CD43 on 
hematopoietic progenitor cells (HPC) and kills the cells after 48 h of 
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incubation [32]. Another antibody, Rituximab, upon hyper-crosslinking with 
goat anti-human (GAH) secondary antibody induces cell death in non-
hodgkin’s lymphomas after 20 h of incubation [33]. There are also potent 
cytotoxic antibodies such as RAV12 which kills COLO 205 colon tumour cells 
within 30 min [34]. The mAb 14F7 kills L1210 murine tumour cell line within 3 
h while anti-Porimin kills Jurkat cells within 20 mins of incubation [35,36]. 
Although these antibodies possess cytotoxic properties on their target cells, 
the death mechanisms induced are different. MEM-59 and Rituximab induce 
apoptosis while the RAV12, 14F7 and anti-Porimin caused the cells to die via 
oncosis. These different mechanisms of cell death will be described in greater 
detail in the later sections. 
 
2.5  Various Phases and Modes of Cell Death 
Cell death is important for normal development of an organism and is 
essential in the maintenance of tissue homeostasis [37,38]. Following a lethal 
injury, cells undergo 3 phases of cell death [39]: 
(1) the ‘pre-lethal’ phase which is often reversible; 
(2) the ‘point-of-no-return’ or cell death; and  
(3) postmortem autolytic and degradative changes.  
Following an injury, cells undergo a series of responses that 
collectively form a disease process. Many injuries to cells are sub-lethal in 
which the cells are able to survive in some altered or new steady state. 
Examples include vacuolization from dilatation of lysosomes and triglyceride 
accumulation. On the other hand, certain injuries, e.g. complete ischemia, are 
often lethal to cells and following a period of reversible reactions (pre-lethal 
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phase), the cells die and undergo a series of degradative reactions. The 2 
common modes of cell death are apoptosis and oncosis [38-43].  
 
 
2.6 Apoptosis 
Apoptosis plays an essential role in the normal development and 
function of multicellular organisms such as cell deletion during embryonic 
development and balancing cell numbers in continuously renewing tissues. 
Dysregulation of apoptosis has been implicated in the development of several 
diseases like Alzheimers, cancer and auto-immune diseases [44]. 
The term ‘apoptosis’ was first introduced by John Kerr in 1972. This 
mode of cell death is associated with a distinct set of physical and 
biochemical changes to the cytoplasm, nucleus and the plasma membrane. 
Cells undergoing apoptosis exhibit a reduction in size and become granular. 
Changes to the plasma membrane (formation of ‘membrane blebs’) and 
cytoskeleton lead to the formation of apoptotic bodies that enclose fragments 
of nucleus and cytoplasm. The apoptotic bodies display phagocytic signals on 
the outer membrane and are subsequently engulfed and digested by 
phagocytes and neighbouring endothelial cells.  Consequently, these cell 
corpses are cleared from the tissue and no inflammatory response is triggered 
during this process. The absence of inflammation is considered as the most 
characteristic feature of apoptosis compared to other modes of cell death 
[38,40,42,45]. 
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2.6.1 Characteristics of apoptosis 
Apoptosis is an organized and tightly controlled process. In most 
apoptosis models, cell death begins 12 to 24 h after the initiation of a trigger 
[41]. Cells undergoing apoptosis exhibit several biochemical modifications 
such as protein cleavage, protein cross-linking, DNA breakdown, and 
phagocytic recognition [38,42,45]. Table 2.1 summarizes the hallmarks of 
apotosis and the assays that can be carried out. 
 
Table 2.1 Hallmarks of apoptosis and their respective assays. 
   
Hallmarks  Assays 
   
Caspase activation Measure of various caspase activity 
   
Phosphatidylserine externalization Annexin V detection 
  
DNA fragmentation TUNEL assay 
  
 
 
 
2.6.1.1 Activation of caspases 
Caspases are widely expressed as inactive proenzymes in most cells. 
They have proteolytic activity and are able to cleave proteins at aspartic acid 
residues, although different caspases have different specificities involving 
recognition of neighboring amino acids [44-48]. Once activated, these 
caspases can activate other procaspases. Some procaspases can also 
aggregate and autoactivate. This proteolytic cascade, in which one caspase 
activate other caspases, amplifies the apoptotic signaling pathway and leads 
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to rapid cell death. Once caspases are activated, irreversible commitment 
towards cell death is inevitable. Caspases have also been identified and 
broadly categorized into initiators (caspase-2,-8,-9,-10) and effectors or 
executioners (caspase-3,-6,-7). 
 
 
2.6.1.2 Exposure of phosphatidylserine (PS) 
Another biochemical feature of apoptosis is the expression of cell 
surface markers that result in the early phagocytic recognition of apoptotic 
cells [45,49]. PS, normally sequestered in the inner plasma membrane, is 
externalized and displayed on the outer plasma membrane during apoptosis. 
PS can be detected with Annexin V, a recombinant PS-binding protein that 
interacts strongly and specifically with PS residues. Annexin V has been 
commonly used for the detection of early apoptosis [49,50]. 
  
2.6.1.3 Fragmentation of DNA 
The formation of distinct DNA fragements is a biochemical hallmark of 
late apoptosis as depicted in Figure 2.3a [44,45,51,52]. The caspase-
activated DNase (CAD) is inactivated when it is bound to the inhibitor, iCAD 
(Figure 2.3b). During apoptosis, iCAD is cleaved by caspases which leads to 
the release of the active endonuclease CAD. CAD enters the nucleus where it 
degrades the chromosomal DNA and produces the characteristic 
internucleosomal DNA cleavage or ‘laddering’ of DNA on agarose gel 
electrophoresis [44,52,53].  
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Figure 2.3 DNA fragmentation during apoptosis. (a) Laddering of DNA fragments on an 
agarose gel electrophoresis. (b) CAD is cleaved from iCAD by caspases during apoptosis. 
Activated CAD translocates to the nucleus and degrades chromosomal DNA.  
 
 
 
 Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) is a common method for detecting DNA fragmentation that results 
from apoptotic signaling cascades [54]. The assay relies on the presence of 
nicks in the DNA which enables the enzyme, terminal deoxynucleotidyl 
transferase (TDT), to catalyze the addition of dUTPs that are secondarily 
labeled with a marker.  
 
 
2.7 Apoptosis and Programmed Cell Death 
 
Apoptosis has been used synonymously with programmed cell death. 
However, programmed cell death is strictly not apoptosis [42]. Programmed 
cell death received its name before apoptosis and it refers to situations in 
which cells are programmed to die at a fixed time. As pointed out by Majno 
and Joris, not all cell death occurring in the course of normal animal 
development have apoptotic features [37]. Thus, as originally intended, 
programmed cell death describes the inclusive phenomena of all cell deaths 
Ladder 
DNA  
Fragments 
CAD 
ICAD 
Apoptotic stimuli 
Caspases 
Inactive ICAD 
Active CAD 
Nucleus 
DNA fragmentation 
(a) (b) 
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that occur normally in the development of a species, with highly reproducible 
timing and location [41]. In other words, when programmed cell death occurs, 
the death mode can be either apoptosis or oncosis. 
 
2.8 Oncosis 
Oncosis (derived from the word “onkos” which means swelling) was 
proposed in 1910 by von Reckling-hausen to describe a form of cell death 
distinct from apoptosis [42,55,56]. It generally represents a response to gross 
injury and can be induced by an overdose of cytotoxic agents [55,56]. Oncosis 
usually occurs within seconds to minutes following application of the injury 
and the early changes include marked alterations in cell shape and volume 
[39,57]. Oncotic cell death is characterized by cell swelling, organelle swelling, 
vacuolization and increase in membrane permeability [39,42,55,57]. The 
molecular and biochemical mechanisms underlying oncosis are still unclear. 
Some studies have shown that oncosis is caused by failure of the ionic pumps 
of the plasma membrane and decreased levels of cellular ATP 
[37,39,42,55,57]. 
 
2.8.1 Characteristic of oncosis 
The characteristics of oncotic cell death are summarized in Table 2.2. 
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Table 2.2 Hallmarks of oncosis and their respective assays. 
   
Hallmarks  Assays 
   
Rapid cell death, occurs within seconds to 
minutes  
- 
   
Progressive increase in membrane 
permeability 
Uptake of trypan blue/propidium iodide; 
uptake of dextran beads of various 
molecular weights (MW) 
  
Leakage of intracellular constituents Change in lactate dehydrogenase (LDH) 
concentration 
  
Cytoskeleton protein denaturation Detection of cytoskeleton proteins 
- western blotting 
  
Pore formation of plasma membrane Scanning electron microscopy 
  
 
 
2.8.1.1 Rapid cell death 
In apoptosis, cell death occurs between 12 h to 24 h post initiation [41]. 
Koopman et. al. showed that when B cells were induced to undergo apoptosis 
upon culture at low serum concentration, subpopulation of the cells were 
stained positive for Annexin V after 56 h, indicating the start of apoptosis [50].  
In another study by Zhang et. al., hyper-crosslinking of Rituximab with goat 
anti-human (GAH) secondary antibody or with Dynabeads or dextran polymer, 
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induced apoptosis in non-Hodgkin’s lymphomas [33]. The incubation time 
required was between 18-20 h. 
On the contrary, in oncosis, cell death can occur as fast as seconds or 
minutes [39,57]. When renal proximal tubules (RPT) were incubated under 
anoxia, PI uptake occurred as fast as 5 min and the release of LDH from the 
cells was observed as quickly as 15 min [58]. The mAb, anti-Porimin, kills 
Jurkat cells via oncosis and cell death occurs within 20 min of incubation [36]. 
 
2.8.1.2 Increase in membrane permeability 
During oncosis, the cells experience progressive increase in 
membrane permeability [42,58,59]. Chen et al. demonstrated 3 different 
permeability phases in freshly isolated rabbit renal proximal tubules (RPT) 
subjected to anoxia. Their results demonstrated that anoxia increases the 
permeability of the plasma membrane in a time- and size- dependent manner. 
The first phase allowed the entry of propidium iodide (PI, a cell-impermeable 
DNA dye, MW 668 Da). The second phase allowed the entry of dextrans up to 
3 kDa, and the last phase allowed the entry of 70-kDa dextrans and the 
release of cytosolic enzymes, such as LDH (MW=130 kDa). Similar plasma 
membrane permeability changes were observed in Madin-Darby canine 
kidney (MDCK) cells and hepatic sinusoidal endothelial cells when they were 
exposed to chemical hypoxia [60,61]. As a consequence of the increase in 
membrane permeability during oncotic cell death, release of intracellular 
constituents such as LDH was observed [58,59,62]. Similar LDH releases 
during oncosis were also reported by Ma et. al. and Liu et. al. [57]. 
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2.8.1.3 Protein denaturation 
During oncosis, protein hydrolysis and/or denaturation occurs [42]. 
Recent studies have linked the progressive membrane permeability changes 
during oncosis to proteolysis of cytoskeletal proteins, such as α-actinin, 
paxillin, talin and vinculin [55]. In a study by Liu et. al., when RPT cells were 
exposed to hypoxia for 30 min or treated with antimycin A for 30 min, 
degradation of α-actinin, paxillin, talin and vinculin was observed [62]. In 
addition, there are growing evidences that the proteolysis of these 
cytoskeletal proteins are mediated by calpains, a family of 14 Ca2+-activated 
cysteine proteases [38,55,62-65]. 
 
 
2.9 Apoptosis, Oncosis and Necrosis  
In the review by Majno and Joris, they described that necrosis is not a 
form of cell death, but refers to the morphological alterations secondary to cell 
death by any mechanism, including apoptosis [38,40,42]. In other words, 
necrosis defines the postmortem cellular changes [39]. On the other hand, 
oncosis and apoptosis are 2 forms of cell death, which leads to necrosis 
[38,40,42]. Apoptosis and oncosis are therefore pre-mortal processes, while 
necrosis is a post-mortal condition. Figure 2.4 illustrates the relationship 
between apoptosis, oncosis and nerosis [38]. 
 
 21
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Illustration of apoptosis and oncosis as described by Majno and Joris. 
Apoptosis and oncosis are 2 forms of cell death; whereas necrosis is the end stage of either 
cell death. At necrosis, cell death by apoptosis or oncosis is termed as apoptotic necrosis or 
oncotic necrosis respectively. 
 
 
 
2.10 Apoptosis Versus Oncosis 
Recent studies have demonstrated that in response to a given death 
stimulus, there is often a continuum of apoptosis and necrosis. Many insults 
induce apoptosis at lower doses and necrosis at higher doses. Even in 
response to a certain dose of death-inducing agent, features of both apoptosis 
and necrosis may coexist in the same cell [37]. Nonetheless, apoptosis and 
oncosis are 2 forms of cell death which bear distinct different characteristics. 
Table 2.3 summarizes the differences between apoptosis and oncosis [37,45]. 
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Table 2.3 Differences between apoptosis and oncosis. 
   
Apoptosis  Oncosis 
   
Cell death occurs between 12-24 hr Rapid cell death, occurs within seconds to 
minutes 
   
Cell shrinkage Cell swelling 
  
Plasma membrane integrity maintained Plasma membrane integrity lost 
  
Ordered DNA degradation Random DNA degradation 
  
Cytoplasm retained in apoptotic bodies Cytoplasm released 
  
No inflammation Inflammation usually present 
  
 
 
2.11 Antibody-induced Cell Death 
Many reports have shown that cell death can be induced when cells 
are incubated with specific antibodies (Section 2.4). The mechanism of these 
antibody-mediated cell deaths can be either apoptosis or oncosis which are 
described in the following sections. 
 
2.11.1 Antibody-induced apoptosis 
Bazil et. al. showed that the monoclonal antibody, MEM-59, induced 
apoptosis in hematopoietic progenitor cells (HPC) after incubation [32]. MEM-
59 recognizes CD43, an adhesion molecule highly expressed on HPC. After 
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48 h of incubation with the antibody, the phenotype of HPC was 
characteristics of apoptosis such as cell shrinkage and DNA fragmentation 
(Figure 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 MEM-59 induces apoptosis in HPC [32]. After 48 h incubation with MEM-59, 
HPC shows characteristic of apoptosis. Apoptotic HPC (a) undergoes cell shrinkage as 
indicated by the black arrows, (b) shows marked increase in DNA fragmentation (increase in 
fluorescence level) via terminal deoxynucleotidyl transferase assay. 
 
 
 
In another study by Zhang et. al., hyper-crosslinking of Rituximab with 
goat anti-human (GAH) secondary antibody or with Dynabeads or dextran 
polymer, induced apoptosis in non-Hodgkin’s lymphomas [33]. The incubation 
time required was between 18-20 h and the cells exhibited apoptotic 
characteristics such as PS exposure (as detected by Annexin V), DNA 
fragmentation and increase in caspase-3 activity (Figure 2.6). In addition, 
Rituximab hyper-crosslinked with dextran polymer was able to cause marked 
tumour regression in their xenograft model (Figure 2.7). 
 
(b) (a) Control 
MEM-59 
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Figure 2.6 Hyper-crosslinked Rituximab induces apoptosis in non-Hodgkin’s 
lymphomas [33]. After 18-20 h incubation with hyper-crosslinked Rituximab, non-Hodgkin’s 
lymphomas show characteristic of apoptosis. Treatment with hyper-crosslinked Rituximab are 
boxed in red. (a) Apoptotic cells as determined by PS exposure. (b) DNA fragmentation via 
TUNEL. (c) Measure of caspase-3 activity. 
 
(a) (c) 
(b) 
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Figure 2.7 Rituximab hyper-crosslinked with dextran causes tumour regression in 
xenografts [33]. 
 
 
 
2.11.2 Antibody-induced oncosis 
There are also reports of antibodies inducing oncotic cell death. RAV12 
(IgG1 subclass) is a chimeric mAb derived from the parental mAb KID3. Both 
antibodies exhibit potent cytotoxic activity in vitro against COLO 205 colon 
tumor cells [34]. Interestingly, RAV12-mediated cytotoxicity requires the 
cross-linking of cellular components: Fab fragments of RAV12 did not induce 
cytotoxicity, whereas cross-linking of the Fab fragments with a secondary 
antibody restored the cytotoxic activity to the level of the intact antibody.  
Following RAV12 and KID3 treatment of COLO 205 cells in vitro, the 
cells undergo oncosis. Microscopic examination revealed that there was rapid 
swelling within 1 h following RAV12 treatment (Figure 2.8a). Double staining 
for RAV12 and filamentous-actin showed that RAV12 associated with the 
plasma membrane and treatment with RAV12 caused disruption of the actin 
cytoskeleton (Figure 2.8a). Time-lapse microscopy also revealed that cellular 
swelling led to membrane leakage following treatment with KID3 (Figure 
Rituximab hyper-
crosslinked with 
dextran 
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2.8b). Consequently, elevated LDH was detected in the medium within 30 min 
of antibody treatment, indicative of membrane rupture. In addition, RAV12 
was able to inhibit tumour growth in vivo. 
 
 
 
 
 
 
 
Figure 2.8 RAV12 and KID3 induces oncosis in COLO 205 colon tumour cells [34]. (a) 
Swelling of cells and disruption of actin after 1 h treatment with RAV12. (b) KID3 causes cell 
swelling as indicated by the arrows. 
 
 
 
The cell death following KID3 treatment did not exhibit markers of 
apoptotic cell death. The KID3 treated cells did not exhibit Annexin V staining 
and DNA fragmentation or changes in cell cycle. 
 Two other examples of antibodies that kill cells via oncosis [35,36] are 
mAbs 14F7 and anti-Porimin.  The mAb 14F7 kills L1210 murine tumour cell 
line within 3 h of incubation while anti-Porimin kills Jurkat cells within 20 min 
of incubation. In both studies, the cell death mechanism was independent of 
complement and did not resemble apoptosis (no DNA fragmentation or 
caspase activation was observed). However, both antibodies caused increase 
in cell membrane permeability as evident from PI uptake. Interestingly, cells 
treated with the two antibodies underwent rapid and apparent cell aggregation 
and the formation of pores on the cell membrane were visualized under 
scanning electron microscope (SEM) (Figure 2.9). Similar to RAV12, the mAb 
(a) (b) 
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14F7-induced cell death also involved the re-arrangement of cytoskeletal 
proteins.  
 
 
 
 
 
 
 
Figure 2.9 Formation of pores through cell membrane and cell aggregation during 
oncosis. In both studies, cells treated with antibodies experienced rapid and apparent cell 
aggregation, and formation of pores through the cell membrane as opposed to the control. (a) 
L1210 murine tumour cell line after treatment with mAb 14F7 [35]. (b) Jurkat cells after 
treatment with anti-Porimin [36]. 
 
 
 
2.12 Summary  
Despite the immense potential hESCs hold for regenerative medicine, 
safety concerns associated with the presence of residual hESCs in the 
differentiated cell product remains. Studies have shown that undifferentiated 
hESCs can form teratomas in SCID mouse models and as few as 245 
undifferentiated hESCs is sufficient for teratoma formation in SCID mouse 
[12]. To make hESC-derivative products safer for cell-based therapies, 
several methods were proposed. One of the methods proposed is to use 
specific antibodies to positively or negatively select for the desired cell 
population. An alternate method is to use cytotoxic antibodies to directly kill 
residual undifferentiated hESCs. Cytotoxic antibodies that kill cells via 
apoptosis or oncosis have been used to eliminate undesired cells in many 
studies.  
Control mAb 14F7 
(a) 
anti-Porimin 
Control 
x 2,000 
Magnification 
x 11,000 
Magnification 
(b) 
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CHAPTER 3 MATERIALS AND METHODS 
 
3.1 Cell Culture 
3.1.1 Human embryonic stem cells and induced pluripotent stem cells 
Human embryonic stem cells line, HES-3 (46 X,X) was obtained from 
ES Cell International (ESI). The cells were cultured at 37oC/5% CO2 on 
matrigel-coated culture dishes supplemented with conditioned media (CM) 
from immortalized mouse feeders, ΔE-MEF [19]. The media used for culturing 
hESCs was KNOCKOUT (KO) media which contained 85% KO–DMEM 
supplemented with 15% KO serum replacer, 1 mM L-glutamine, 1% 
nonessential amino acids, 0.1 mM 2-mercaptoethanol, and 5 ng/mL of 
recombinant human fibroblast growth factor-2 (FGF-2) (Invitrogen). The hESC 
cultures were passaged as described previously [19,20]. Briefly, once the 
cultures reached confluency, the cells were enzymatically treated with 
collagenase IV (200 U/mL) and dissociated into small clumps (~100 to 1000 
cells/clump) by repeated pipetting, after which the cells were reseeded at a 
1:4 split ratio on fresh matrigel-coated culture dishes. Culture dishes were 
pre-incubated at 4oC overnight with matrigel (Becton Dickinson) diluted in cold 
KO–DMEM (1:30 dilution). 
Induced pluripotent stem cells, ESIMR90 and ES4SKIN reprogrammed 
from fetal lung fibroblastsand neonatal foreskin fibroblasts respectively, were 
obtained from Prof James Thomson [66,67]. The iPS cells were cultured as 
described for hESC, with the exception that 100 ng/ml of FGF-2 was 
supplemented to the CM instead of 5 ng/ml.  
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3.1.2 Mouse embryonic fibroblast and conditioned media (CM) 
 Monolayers of immortalized mouse embryonic fibroblast, E-MEF, 
were grown to confluency in T-flasks and treated with 10 g/ml mitomycin-C 
for 2.5-3 h. Following treatment, cells were detached with 0.25% trypsin-
EDTA, seeded onto culture dishes at a density of 8 x 104 cells/cm2 and 
incubated overnight to facilitate adhesion[20], after which the feeders were 
equilibrated in KO media and CM was collected every 24 h after the addition 
of fresh KO media [19]. The CM was clarified by filtration (0.22 μm) and 
supplemented with 5 ng/ml of FGF-2 prior to addition to hESC cultures.  
 
3.1.3 IMR90 fibroblasts and Foreskin fibroblasts 
IMR90 (CCL-186™) and Foreskin fibroblasts (CRL-2522™) were 
obtained from ATCC and were cultured in medium consisting of 90% DMEM 
high glucose, 10% FBS, 2mM L-glutamine, 25U/ml penicillin and 25 g/ml 
streptomycin (Invitrogen). Upon confluency, cells were washed in PBS, 
detached with 0.25% trypsin–ethylene-diamine tetraacetic acid (EDTA), and 
re-plated at a ratio of 1:4.  
 
3.2 Spontaneous Differentiation of hESC 
To induce hESC differentiation in vitro, hESCs were harvested as 
clumps and cultured as embryoid bodies (EB) for 8 days in EB-medium (80% 
KO-DMEM, 20% FCS, 25 U/ml penicillin, 25 μg/ml streptomycin, 2 mM L-
glutamine, 0.1mM NEAA, and 0.1 mM 2-mercaptoethanol) on non-adherent 
suspension culture dishes (Corning). Subsequently, the EB were dissociated 
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with trypsin and plated on gelatinized culture dishes [68]. Alternatively, hESCs 
were cultured as described in Section 3.1.1 but in the absence of FGF-2. 
 
3.3 Flow Cytometry Analysis 
Cells were harvested as single cell suspensions using trypsin, 
resuspended at 2 x 105 cells per 10 μl volume in 1% BSA/PBS and incubated 
for 45 min with each mAb clone (150 μl culture supernatant or 5 μg purified 
mAb in 200 μl 1% BSA/PBS) or mAb to TRA-1-60 (2.5 μg in 200 μl 1% 
BSA/PBS, Chemicon, MAB4360), human podocalyxin (PODXL, R&D 
systems) and polyclonal antibody (pAb) to human PODXL (5 μg in 200 μl 1% 
BSA/PBS, R&D systems). Cells were then washed with cold 1% BSA/PBS, 
and further incubated for 15 min with a 1:500 dilution of goat α-mouse 
antibody FITC-conjugated (DAKO). After incubation, the cells were again 
washed and resuspended in 1% BSA/PBS and 1.25 mg/ml propidium iodide 
(PI) for analysis on a FACScan (Becton Dickinson FACS Calibur).  
For analysis of TRA-1-60 and PODXL co-expression, hESCs were 
incubated with anti-TRA-1-60 primary antibody (10 g/ml, Chemicon) and 
washed with 1% BSA/PBS as described previously. Cells were then incubated 
for 15 min with a 1:200 dilution of goat α-mouse antibody APC-conjugated 
(BD Pharmingen) followed by a wash. Finally, the cells were incubated with 
AlexaFluor®488-labeled-mAb 84 (25 g/ml) for an additional 15 min, washed 
and resuspended in 1% BSA/PBS for analysis.  
For triple staining of hESCs, cells were incubated with 
AlexaFluor®488-labeled-mAb 84 (25 g/ml) and AlexaFluor®647-labeled- 
TRA-1-60 for 45 min at 4oC. After incubation, the cells were washed and 
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resuspended in 1% BSA/PBS and 1.25 mg/ml propidium iodide (PI) for 
analysis on a FACScan (Becton Dickinson FACS Calibur). 
 
3.4 Conjugation of Antibodies to Alexafluor  
Labeling of antibodies was carried out with AlexaFluor® 488 and 
AlexaFluor® 647 Monoclonal Antibody Labeling Kit (Molecular Probes). 100 µl 
of purified antibody (1mg/ml) was mixed with the vial of reactive dye and 
incubated for 1 h at room temperature. The reaction solution was 
subsequently loaded onto the supplied purification column and the purified 
AlexaFluor®488-conjugated mAb was collected in the flow through. 
 
 
3.5 Cytotoxicity Assay 
Cytotoxicity of mAb 84 on hESCs was evaluated using propidium 
iodide (PI) exclusion assays and flow cytometry. Cells were harvested as 
single cell suspensions using trypsin, resuspended at 2 x 105 cells per 10 μl 
volume in 1% BSA/PBS and incubated for 45 min with each mAb (150 μl 
culture supernatant or 5 μg purified mAb in 200 μl 1% BSA/PBS). Thereafter, 
cells were washed and resuspended in 1% BSA/PBS containing 1.25 mg/ml 
propidium iodide (PI) and analyzed on a FACScan (Becton Dickinson FACS 
Calibur) with detection emission in the FL-3 channel. As controls, cells were 
incubated either with the isotype control, mAb 85, or not treated with any 
antibodies. All incubations were performed at 4oC unless otherwise indicated.  
For hypercross-linking experiments, hESCs after primary mAb 
incubation were washed and further incubated with a goat α-mouse 
secondary antibody (5 μg in 200 μl 1% BSA/PBS, DAKO) for 45 min. The 
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commercially available primary antibodies used were mAb to human PODXL 
or pAb to human PODXL (5 μg in 200 μl 1% BSA/PBS, R&D systems). For 
dosage studies, hESCs were incubated with 0.1, 0.5, 1, 5 and 15 μg purified 
mAb 84 in 200 μl 1% BSA/PBS. For time course studies, HES-3 cells were 
incubated with 5 μg purified mAb 84 in 200 μl 1% BSA/PBS and harvested for 
analysis at 15, 30 and 45 min after addition of the mAb. As a negative control, 
cells were incubated with the isotype control, mAb 85. All incubations were 
performed at 4oC unless otherwise indicated. To validate the results obtained 
using PI exclusion assays, viability for each sample was also determined 
using trypan blue exclusion.  
 
3.6 Small Scale Purification of mAb 84 and mAb 85 
mAb 84 (~100 μg) was directly captured onto Protein A PhyTip® 
columns (5 μl resin bed). For mAb 85 purification, biotinylated rabbit-anti-
mouse-anti-IgM (1:20 dilution in PBS, Open Biosystems) was first bound to 
Streptavidin PhyTip® columns (5 μl resin bed) and mAb 85 (~100 μg) was 
subsequently captured. After washing away the unbound proteins with Wash 
Buffer I (10 mM NaH2PO4/140 mM NaCl pH 7.4), the antibodies were eluted 
at low pH with Elution Buffer (200 mM NaH2PO4/140 mM NaCl pH 2.5) and 
neutralized immediately with 1 M Tris-Cl pH 9.0. Total antibody concentration 
was quantified with DC Protein Assay (Bio-Rad Laboratories).  
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3.7 Immuno-precipitation 
hESCs were grown to confluence in 6 cm Petri dishes (Falcon) and 
lysed by scraping in 2% Triton/PBS+. The cell lysate was clarified by 
centrifugation and used immediately for immunoprecipitation (IP). IP of the 
antigen was carried out using the automated MEA system (Phynexus, Inc). 
Briefly, mAb 84 (~100 μg) was directly captured onto Protein A PhyTip® 
columns (5 μl resin bed). After washing away the unbound proteins with Wash 
Buffer I (10 mM NaH2PO4/140 mM NaCl pH 7.4), clarified cell lysate from 5 x 
106 cells was passed through the column functionalized with mAb 84. The 
column was further washed with Wash Buffer II (140 mM NaCl pH 7.4) and 
bound proteins were eluted at low pH with Elution Buffer (200 mM 
NaH2PO4/140 mM NaCl pH 2.5) and neutralized immediately with 1 M Tris-Cl 
pH 9.0. The eluate was stored at 4oC for further analysis. 
 
3.8 SDS–PAGE and Western Blot Analysis 
Samples were separated by SDS-PAGE (NuPAGE 4-12% gradient gel, 
Invitrogen) under reducing conditions followed by either Western blotting or 
silver staining. For Western Blotting, resolved proteins were transferred onto 
PVDF membrane (Millipore) at 110 V for 75 min and immunoblotted with 
appropriately diluted antibodies in PBS containing 2.5% skim milk and 0.05% 
Tween 20, followed by goat α-mouse antibodies HRP-conjugated (1:10000 
dilution, DAKO). Bound antibodies were detected by ECL (Amersham). Silver 
staining was performed using SilverQuest silver staining kit (Invitrogen) 
according to the manufacturer’s protocol and the protein band corresponding 
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to the band on the Western Blot was manually excised for mass spectrometry 
analysis. 
For cytoskeleton degradation assay, hESCs were incubated with the 
mAbs for 45 min, harvested and lysed with 2% Triton X-100 (Bio-Rad 
Laboratories) in PBS+. The lysates were clarified via centrifugation, total 
protein concentration quantified with DC Protein Assay (Bio-Rad Laboratories) 
and Western blot analysis carried out as described. For time course studies, 
the cells were incubated with the mAbs and at every 10 min interval, cells 
were harvested and lysed prior to Western blot analysis. The antibodies used 
for immunoblotting were anti-actin, anti-α-actinin, anti-paxillin, anti-talin, anti-
vinculin, anti-integrin-β-1, anti-focal adhesion kinase (FAK) and anti-α/β-
tubulin (Millipore). Anti-NHERF-1/2 and anti-ezrin were purchased from Santa 
Cruz and Invitrogen respectively. 
 
3.9 Validation of Target Antigen 
IP of PODXL with mAb 84 was carried out as described and Western 
blot analysis was subsequently performed. The primary antibodies used for 
validating the target antigen of mAb 84 were mAb to human PODXL or pAb to 
human PODXL (1:200 dilution, R&D systems). 
 
3.10 Mass Spectrometry Analysis 
The excised gel band was soaked overnight at 4oC in washing solution 
(2.5 mM ammonium bicarbonate in 50% acetonitrile) followed by 20 min 
incubation at 37oC after a change in washing buffer. The excised gel was then 
subjected to in-gel proteolysis with trypsin following reduction and s-alkylation 
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of cysteine residues with iodoacetamide. Extracted peptides were subjected 
to analysis using mass spectrometry as described but with the following 
modifications [69]. The analysis was performed on a QSTAR-XL (Applied 
Biosystems/Sciex) using Information Dependent Acquisition (IDA) mode 
under control of the Analyst-QS software v1.1. Each multiply-charged (2+ to 
4+) parent mass ion with a threshold greater than 8 counts/sec within a mass 
range of 300 and 2000 amu was selected for fragmentation and subsequent 
MS/MS analysis using nitrogen gas at a setting of 4 and the collision energy 
set to automatic allowing increasing energy with increasing ion mass. Proteins 
were identified by searching the raw data files (.wiff) against the human 
subset of the UniProt database (EBI) using the Mascot search engine (Matrix 
Science). 
 
3.11 Removal of N-link Glycans 
IP of PODXL with mAb 84 was carried out as described and removal of 
N-link glycans was carried out with PNGase F (New England Biolabs). 20 µg 
of glycoprotein was denatured in 1x Glycoprotein Denaturing Buffer at 100oC 
for 10 min. Subsequently, one-tenth volume of 10x G7 Reaction Buffer and 
10% NP-40 was added and incubated with 5 µl PNGase F at 37oC for an 
hour. Western blot analysis was carried out on the deglycosylated protein.  
 
3.12 Removal of O-link Glycan 
Removal of O-link glycans was performed with E-DEGLY kit (SIGMA). 
Briefly, 20 µg of purified glycoprotein was topped up with deionized water to 
30 µl in a microcentrifuge tube. 10 µl of 5x Reaction Buffer and 2.5 µl of 
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Denaturing Solution was added and incubated at 100oC for 5 min. The mixture 
was cooled to room temperature and 2.5 µl TRITON X-100 was added. 1 µl of 
α-2(3, 6, 8, 9) Neuraminidase was added and incubated for 3 h at 37oC to 
remove terminal salic acid. Next, the mixture was incubated with 1 µl PNGase 
F for an additional 3 h at 37oC to remove N-link glycans. Finally, the mixture 
was incubated for another 3 h at 37oC with 1 µl O-Glycosidase, 1 µl β(1-
4)Galactosidase and 1 µl β-N-Acetylglucosaminidase to remove O-link 
glycans. Removal of the respective glycans after each incubation step was 
assessed by Western blot analysis. 
 
3.13 In vivo SCID mouse Teratoma Model with hESCs 
To test the teratoma-forming potential of hESCs in vivo, cells were 
harvested by PBS- and treated with antibodies as described above. The 
single-cell suspension of hESCs (4 x 106 cells/per animal in a 50 μl volume) 
was injected directly into the quadriceps of the right hind leg of a male SCID 
mouse. Animal experiments were performed in accordance with NIH and 
NACLAR guidelines (NUS IRB protocol 05-020, Biopolis IACUC approval 
050008). Teratoma formation was monitored visually using a simple grading 
system that was confirmed by caliper measurements: grade 0 = no visible 
teratoma (6.32 mm average maximal hind leg diameter), grade 1 = teratoma 
just detectable (10.55 mm average), grade 2 = teratoma obvious (13.2 mm 
average), and grade 3 = teratoma impedes locomotion (14.52 mm average). 
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3.14 SCID Teratoma Model with Mix Cell Population  
To establish an in vivo model using mixed cell populations instead of 
undifferentied hESCs, hESCs were spontaneously differentiated to EB (as 
described previously) or cultured in the absence of FGF-2. Cells were 
subsequently harvested with trypsin and PBS- respectively to obtain a single 
cell suspension.  Cells were then treated with antibodies as described above 
and was injected directly into the quadriceps of the right hind leg of a male 
SCID mouse (6 x 106 cells/per animal in 60 μl PBS + 30 μl Matrigel). 
 
3.15 Induction of Apoptosis via Ultra-violet (UV) Irradiation 
Confluent hESC cultures were exposed to 200 mJ of UV using a UV 
cross-linker (UV Stratalinker 1800) to induce apoptosis [70]. After UV 
exposure, the cells were maintained at 37oC/5% CO2 for 2 h before assaying 
them with the various apoptotic assays. 
 
3.16 Flow Cytometric Analysis of Nuclear DNA Fragmentation  
Nuclear DNA fragmentation was measured via TUNEL assay kit 
(Promega). Cells (1.5 x 106 cells) from each condition were washed twice with 
PBS+ and incubated in 4% methanol-free paraformaldehyde for 20 min on 
ice. Subsequently, the cells were washed, fixed and permeabilized with 5 ml 
of ice cold 70% ethanol and stored overnight at -20oC. The cells were then 
centrifuged at 300 x g for 10 min at 4oC and washed with 5 ml PBS+. The 
centrifugation step was repeated and the cells were resuspended in 1 ml 
buffer and transferred to a microcentrifuge tube. The cells were again 
centrifuged at 300 x g for 10 min at 4oC and the supernatant removed. The 
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pellets were resuspended in 80 l equilibration buffer and incubated at room 
temperature for 5 min, spun down and the supernatant removed. The pellets 
were then resuspended in 50 l of rTDT incubation buffer and incubated at 
37oC for 1 h. During the incubation, the cells were resuspended by pipeting at 
15 min intervals. The reactions were terminated by adding 1 ml of 20 mM 
EDTA to each sample and vortexing gently. The cells were then washed 3 
times with 0.1% Triton X-100/5% (w/v) BSA in PBS and finally resuspended in 
500 l PI solution (5 g/ml in PBS). The samples were analyzed immediately 
on the flow cytometer (FACScan, Becton Dickinson FACS Calibur). The green 
fluorescence of fluoresein-12-dUTP and PI emissions were detected in the 
FL-1 and FL-3 channels respectively. 
 
3.17 Measurment of Caspases Activities  
Caspase activities, namely Caspases-2/3/8/9, were measured using 
ApoAlert® Caspase Profiling Plate (Clontech). Modifications were made to the 
protocol provided by the supplier. After subjecting the cells to UV or mAb 
treatments, 1 x 106 cells were taken from each condition and lysed with 450 l 
of ice cold lysis buffer. The cell lysates were centrifuged at 13 200 x g at 4oC 
for 5 min to pellet cellular debris. The supernatants were transferred to new 
microcentrifuge tubes and placed on ice. The total protein for each lysate was 
determined using Coomassie Blue Plus reagents. Prior to adding the samples 
to the assay plate, 50 l of 2X Reaction Buffer/DTT Mix was added to each 
well of the assay plate and incubated at 37oC for 5 min. Fifty microlitres of the 
appropriate cell lysate was then transferred to the wells. The plate was further 
incubated at 37oC for 2 h and subsequently analyzed using a fluorescence 
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plate reader (TECAN Infinite M200) at an excitation wavelength of 380 nm 
and emission wavelength of 460 nm. Additional controls were also set up. 
Prior to induction of apoptosis or antibody incubation, cells were incubated for 
30 min with ZVAD (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]) in PBS. 
ZVAD is a broad spectrum inhibitor to caspases. 
 
3.18 Annexin V Assay 
Detection of phosphotidylserine on the outer leaflet of the plasma 
membrane during apoptosis was detected by Annexin V using the Annexin V-
FITC Apoptosis detection kit (Bender MedSystems). After subjecting the cells 
to UV or mAb treatments, 0.5 x 106 cells was centrifuged at 13 200 x g for 1 
min and the pellet washed with the binding buffer provided. The cells were 
again centrifuged and the pellet resuspended in 195 l of binding buffer. 
Subsequently, 5 l of Annexin V-FITC was added and the cells were 
incubated at room temperature for 10 min. The cells were then centrifuged at 
13 200 x g for 1 min and the pellet washed with the binding buffer. The pellet 
was finally resuspended in 200 l buffer and analyzed immediately on the flow 
cytometer (FACScan, Becton Dickinson FACS Calibur). 
 
3.19 Lactate Dehydrogenase (LDH) Release 
LDH released from dead cells is measured using the CytoTox 96 Non-
radioactive Cytotoxicity Assay (Promega). The cells were treated with mAbs 
as described. After incubation with the mAbs, the cells were centrifuged at 13 
200 x g for 1 min and the supernatant kept for LDH activity measurement. For 
total LDH measurement, untreated cells were lysed with the 10x Lysis Buffer 
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provided, centrifuged at 13 200 x g for 1 min to remove cellular debris and the 
supernatant collected. From each supernatant sample, 50 l of supernatant 
was transferred to individual wells of the enzymatic assay plate and 
subsequently, 50 l of reconstituted Substrate Mix was added to each sample 
well. The assay plate was incubated for 30 min at room temperature, 
protected from light. After the incubation, 50 l of Stop Solution was added to 
stop all reactions and absorbance recorded at 490 nm with the TECAN Infinite 
M200. 
 
3.20 Flow Cytometric Analysis of Na+ Release  
Release of intracellular sodium ions was determined using the Sodium 
GreenTM Indicator kit according to the manufacturer’s protocol (Molecular 
Probes). Briefly, 1 x 106 cells were incubated with 10 M Sodium Green, 
tetra(tetramethylammonium) salt at 37oC for 35 min to allow the dye to 
penetrate the cells.  Afterwhich, excess dye was removed after a wash with 
KO-media followed by 2 washes with 1% (w/v) BSA in PBS.  The loaded cells 
were then subjected to various experimental treatments and washed. 
Intracellular levels of dye were analyzed on the flow cytometer (FACScan, 
Becton Dickinson FACS Calibur) through the FL-1 channel. 
 
3.21 Estimation of Pore Size with Dextran Beads  
Dextran conjugates of various molecular weight (3000 MW to 2 x 106 
MW, Molecular Probes) were used to determine the size of the pores formed 
on the plasma membrane of the cells. The dextran conjugates were 
reconstituted in PBS+ according to the supplier’s specification. Ten microlitres 
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of each dextran conjugate was added to cell suspensions (consisting of 2 x 
105 cells) and incubated for 30 min at 37oC. The cells were then washed twice 
with ice cold PBS+ to remove excess dextran conjugates and resuspended in 
200 l buffer. Five microlitres of PI (50mg/ml PBS) was added prior to 
analysis on the flow cytometer (FACScan, Becton Dickinson FACS Calibur). 
The dextran conjugates and PI were analyzed through the FL-1 and FL-3 
channels respectively. 
 
3.22 Visualization of Cell Surface Membrane through Scanning 
Electron Microscopy (SEM) 
After subjecting hESCs to the various experimental conditions, cells 
were washed and resuspended in 2.5% glutaraldehyde in PBS and fixed at 
room temperature for 5 h. After fixing, the cells were washed 2x with PBS+ 
and post-fixed with 1% osium tetroxide (pH 7.4) for 30 min. Subsequently, the 
cells were washed twice with deionised water for 10 min. After the wash, the 
cells were dehydrated in increasing concentration of ethanol from 25% to 
100%.  The cells were then transferred dropwise to 1 mm diameter cover slips 
that were pre-coated with poly-L-lysine (PLL). Prior to SEM analysis, the 
prepared cells were exposed to critical point drying to purge out residual 
ethanol and sputtered with gold. 
 
3.23 Visualization of Antigen Aggregation through SEM 
After treatment with antibodies, the cells were washed and further 
incubated for 15 min with goat α-mouse antibody colloidal gold-conjugated 
(0.2ug/150 ul cell suspension, EY Laboratories). The cells were subsequently 
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fixed and prepared for SEM as described above and sputtered with carbon 
prior to examination.  
 
3.24 Confocal Microscopy 
Cells were treated with the various antibodies as mentioned above and 
washed with 1% BSA/PBS. The cells were then fixed, permeabilized 
(Invitrogen) and blocked with 1% BSA/PBS for 1 h. Subsequently, the cells 
were incubated with primary antibodies to the respective antigens overnight at 
4oC. The antibodies, mAb 84 and mAb 85 (both IgMs) and anti-paxillin (IgG) 
were used at a concentration of 25 µg/ml. The cells were washed and 
incubated with 1:500 dilution of FITC-conjugated goat anti-mouse IgG (γ-
chain specific) antibody (SIGMA), PE-conjugated rabbit anti-mouse IgM 
(OPEN Biosystems) and DAPI (Molecular Probes) for 1 h at room 
temperature. The cells were washed and mounted onto glass slides with anti-
fade reagent (Invitrogen). Localization of the proteins was visualized under a 
confocal microscope (Zeiss). 
 
3.25 Calpain Inhibition 
hESCs were cultured as described and incubated with the calpain 
inhibitors (20 nM) for 24 h. The cells were then harvested and cytotoxicity 
assays was carried out. All calpain inhibitors were from Calbiochem.  
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3.26 Statistical  Analysis 
Data were expressed as means ± standard error of the mean. 
Standard deviations were analyzed via F-test. The 2 means were compared 
with the Student’s t-test. 
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CHAPTER 4 IN VITRO CHARACTERIZATION OF mAb 84 
 
4.1 Introduction 
In order to produce therapeutically useful cells from hESCs, it is 
important to characterize and understand the cellular components and 
pathways that govern their proliferation and differentiation [11,14,15]. One of 
the ways to identify the receptors or antigens involved in hESC regulation is to 
raise antibodies against hESCs surface markers. An additional advantage of 
raising antibodies specific to undifferentiated hESCs is that these antibodies 
can be used to separate the differentiated cells from the undifferentiated cells 
which potentially can form teratomas [1,11-13]. 
Following immunization of BALB/c mice with live cells, we generated a 
panel of antibodies to cell surface markers on undifferentiated hESCs. Figure 
4.1 illustrates the generation of antibodies against hESC surface markers. 
Briefly, live undifferentiated hESCs were injected into BALB/c mice over a 
period of 5 weeks. Post-immunisation, serum was drawn and screened for the 
presence of antibodies that bind to hESCs. The mice were then sacrificed and 
the spleens harvested. The spleenocytes were subsequently fused with Sp2/0 
myeloma cells and after hypoxanthine-aminopterin-thymidine (HAT) selection, 
colonies of hybridomas were isolated. Antibodies produced form the 
hybridomas were further screened against hESCs and various other cell types 
to test their specificity. From this, a panel of 10 mAbs against hESC cell 
markers were identified. Their reactivity to various hESC lines and other cell 
lines are summarized in Table 4.1. Conventional antibodies to hESCs, namely 
SSEA-1, TRA-1-60 and TRA-1-80 are also included for comparison. 
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Figure 4.1 Generation of antibodies against hESC surface markers.  
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From this panel of 10 antibodies, an antibody, mAb 84, was identified 
that not only binds but also kills undifferentiated hESCs. mAb 84 showed 
strong reactivity to the undifferentiated hESC lines (HES-2, HES-3 and HES-
4). However, the reactivity was significantly reduced in hESC-derived EBs, 
mouse ESCs, mouse feeders, human EC cells, and other human cell lines 
(HEK-293 and HeLa). When hESCs were incubated with mAb 84, there was a 
significant decrease in cell size and an increase in PI uptake, which is 
indicative of cell death (Figure 4.2). The ability of mAb 84 to selectively kill 
undifferentiated hESCs is extremely beneficial as mAb 84 can potentially be 
used to remove residual undifferentiated hESCs contaminating differentiated 
cell products prior to therapeutic applications.  
 
 
 
Table 4.1 Summary of mAb reactivity to various cell lines. 
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Figure 4.2 mAb 84 is cytotoxic to hESCs. (a) When hESCs were incubated with mAb 84, 
there was a significant decrease in cell size (from 19% to 73%) compared to hESCs 
incubated with other mAbs. (b) A significant increase in PI uptake was observed when hESCs 
were incubated with mAb 84 (from 12% to 77%).  
 
 
 
This chapter reports the in vitro characterization of mAb 84. The 
antigen target of mAb 84 on hESCs was first identified. Next we went on to 
determine if the cytotoxic effect is unique to mAb 84 or is this cytotoxic effect 
also observed with other mAbs against the same antigen. We also 
investigated the effect of complement, temperature and antibody 
concentration on mAb 84 cytotoxicity and studied its death kinetics. Assays 
were also carried out to investigate if the killing ability of mAb 84 is specific to 
undifferentiated hESCs and to determine the type of glycan which mAb 84 
binds. Studies were also carried out to determine if mAb 84 binds and kills 
induced pluripotent stem cells (iPS cells). 
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4.2 Identification of mAb 84 Target Antigen on hESC 
4.2.1 Identification of Podocalyxin as the antigen target 
To identify the target antigen of mAb 84, immuno-precipitation (IP) was 
carried out using the PhyNexus automated system. Briefly, hESC lysate was 
passed through a PhyTip column containing protein A resin and mAb 84. The 
enriched protein sample was eluted, resolved by polyacrylamide gel 
electropheris and immuno-blotted (IB) with mAb 84. An antigen band of ~190 
kDa was detected (Figure 4.3, Lane 1). The corresponding band on a silver-
stained gel was excised and analyzed by mass spectrometry (MS). From 
protein database search with the peptides obtained, the antigen band was 
identified as podocalyxin-like protein-1 precursor (PCLP1 or PODXL; 
Accession No. O00592). 
To validate that the antigen target is PODXL, IP with mAb 84 was 
repeated and the eluate after PAGE and IB was probed with 2 commercially-
available antibodies to PODXL (Figure 4.3, Lanes 2 and 3). From the Western 
blots, a band of comparable molecular weight was detected in all 3 lanes, 
confirming the identity of the target antigen as PODXL. 
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Figure 4.3 Western blot analysis of target antigen immuno-precipitated by mAb 84. 
Affinity purified antigen from hESC lysate using PhyTip columns containing protein A resin 
and mAb 84 was resolved on SDS-PAGE and subjected to Western blot. Lane 1: IB with mAb 
84; Lane 2: IB with mAb to human PODXL (mAb-PODXL) and Lane 3: IB with polyclonal 
antibody (pAb) to human PODXL (pAb-PODXL). 
  
 
 
4.2.2 Background of PODXL 
PODXL is a heavily glycosylated type-1 transmembrane protein and 
belongs to the CD34 family of sialomucins, which include CD34 and 
endoglycan [71,72]. The human PODXL is localized on chromosome 7q32-
q33 with an open reading frame that encodes for a protein of 528 amino acids 
[73,74]. The extracellular domain of PODXL has 5 potential sites for N-linked 
glycosylation and from amino acids 22 to 295, the high serine and threonine 
content provides numerous sites for potential O-linked glycosylation [74]. The 
predicted molecular weight of PODXL is 54 kDa but the apparent molecular 
weight is approximately 160-165 kDa, due to the extensive glycosylation 
[74,75]. 
PODXL has been reported to have diverse roles depending on the cell 
type. In podocytes, PODXL acts as an anti-adhesion molecule that maintains 
191 kDa 
97 kDa 
64 kDa 
51 kDa 
IB : mAb 84 mAb pAb 
1 2 3 
Lane 
Commercial anti-PODXL 
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the filtration slits open between podocyte foot processes by charge repulsion 
[76,77]. In high endothelial venules, PODXL acts as an adhesion molecule 
binding to L-selectin and mediating the tethering and rolling of lymphocytes 
[72]. 
The presence of PODXL in hESCs was also reported by 
Brandenberger et. al. [78]. In their work, they characterized hESCs at the 
molecular level and through expressed sequence tag (EST) frequency 
analysis, they found that the level of PODXL expression was down-regulated 
by almost 2.5 fold in 7-8 day EB and approximately 7 and 12 fold in 
neuroectoderm-like cells and hepatocyte-like cells respectively. Interestingly, 
at the protein level, Schopperle and DeWolf reported that PODXL underwent 
post-translational glycosylation changes during differention when 2 EC lines 
were exposed to retinoic acid (reduction in MW from 200 kDa to 170 kDa). 
The failure of the carbohydrate-binding antibodies, anti-TRA-1-60 and ati-
TRA-1-81, to bind to the modified PODXL prompted them to suggest the 
presence of a Stem Cell PODXL (SC-PODXL) on pluripotent stem cells [79].  
 
4.3 Cytotoxicity is Unique to mAb 84 
During the characterization of the mAbs in the panel, it was identified 
that mAb 85 also binds to PODXL (Table 4.1). Interestingly, even though mAb 
85 is also an IgM, it does not confer any cytotoxicity on hESCs (Figure 4.4). 
Thus, mAb 85 was consequently used as an isotype control for mAb 84. 
We also proceeded to investigate whether the commercially-available 
antibodies to PODXL exhibited similar cytotoxic effect on hESCs. From Figure 
4.4, it is apparent that although the other 3 sources of antibodies (mAb 85 and 
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mAb/pAb-PODXL) were specific to human PODXL on hESCs, cytotoxicity 
was only observed for mAb 84 and not for other anti-PODXL antibodies. This 
suggests that the binding of mAb 84 is epitope specific rather than antigen 
specific, and that the cytotoxicity is unique to mAb 84. 
 
 
 
Figure 4.4 Only mAb 84 is cytotoxic to hESCs. Cytotoxicity assay was performed by 
incubating hESCs with 5 µg mAb 84, mAb/pAb-PODXL and mAb 85. Only mAb 84 is 
cytotoxicity to hESCs, as opposed to mAb 85 and the commercially available antibodies 
(mAb-PODXL and pAb-PODXL). When the commercially available antibodies were hyper-
crosslinked with goat-anti-mouse (GAM), no cytotoxicity was observed. 
 
 
 
Several groups have previously reported that cell death can be induced 
by hyper-crosslinking of primary antibodies bound to antigens on cells [32-
34,80,81]. Since mAb 84 is an IgM (pentameric) whilst mAb-PODXL and pAb-
PODXL are both IgG (bivalent), we investigated if hyper-crosslinking of mAb-
PODXL or pAb-PODXL with goat-anti-mouse (GAM) antibodies would mimic 
mAb 84- mediated killing of hESCs. Incubation of hESCs with primary 
0 
20 
40 
60 
80 
100 
mAb84 mAb 85 mAb-PODXL pAb-PODXL mAb-
PODXL-GAM
pAb-PODX-
GAM
C
el
l V
ia
bi
lit
y 
(%
)
 52
antibodies followed by GAM antibodies failed to induce a similar cytotoxic 
effect as mAb 84 (Figure 4.4). 
 
 
4.4 Cytotoxicity of mAb 84 is Independent of Complement 
Next, we compared purified and non-purified (culture supernatant) mAb 
84 to determine if complement in fetal bovine serum was required for 
cytotoxicity. We found that mAb 84 was equally cytotoxic to hESCs after 
purification (Figure 4.5) with a killing efficiency of more than 77% at 4oC 
incubation. This result suggests that mAb 84-induced toxicity on hESCs was 
not complement-mediated. In all future experiments, purified mAb 84 was 
used. 
 
 
 
 
 
 
 
 
 
Figure 4.5 Cytotoxicity of mAb 84 is independent of complement. The killing efficiency of 
purified and supernatant mAb 84 (S/N mAb 84) is comparable. In both conditions, more than 
77% of hESCs was killed after 45min incubation at 4oC.  
 
 
 
4.5 Cytotoxicity of mAb 84 is Independent of Temperature 
As all experiments were conducted at 4oC, we went on to investigate 
the effect of temperature on the cytotoxicity of mAb 84. hESCs were 
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incubated with 5 μg mAb 84 at 4oC and at 37oC (Figure 4.6). We found that 
the killing efficiency of mAb 84 was comparable at both temperatures and 
concluded that the cytotoxicity of mAb 84 is independent of temperature. 
 
 
 
 
 
 
 
 
 
Figure 4.6 Cytotoxicity of mAb 84 is independent of temperature. The killing efficiency of 
mAb 84 is comparable at both 4oC and 37oC. (▇) represents mAb 84-treated hESCs and (▇) 
represents mAb 85-treated hESCs. 
 
 
 
4.6 Cytotoxicity of mAb 84 is Dependent on Concentration 
In this dose-response experiment, the concentration of mAb 84 was 
titrated over the range of 0.1-15 μg and added to 2 x 105 cells in a volume of 
200 ul. It was found that the cytotoxic effect of mAb 84 on hESCs was 
concentration-dependent (Figure 4.7). Approximately 1 μg of purified mAb 84 
was sufficient to cause more than 70% decrease in hESC viability, as 
indicated by the red arrow.  
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Figure 4.7 Titer experiment. Cytotoxicity of mAb 84 is dosage dependent.  
 
4.7 Kinetics of mAb 84 Killing of hESCs    
In time course studies, hESCs (2 x 105) were incubated with 5 μg mAb 
84 or mAb 85 and the cells were harvested every 15 min for analysis by PI 
and trypan blue exclusion assays (Figure 4.8 a and b respectively). Through 
the PI exclusion assay, the cytotoxic effect of mAb 84 on hESCs was 
observed as quickly as 15 min after incubation with the viability dropping to 
33%, with a further decrease in viability to 20% after 45 min. These results 
were confirmed by trypan blue exclusion assay although the cytotoxicity 
occurs only 30 min after incubation. This may be due to the fact that the 
trypan blue assay is a less sensitive assay compared to PI exclusion assay.  
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Figure 4.8 Time course assay. mAb 84 kills hESCs as fast as 15 min. (━) represents mAb 
84-treated hESCs and (━) represents mAb 85-treated hESCs (a) Percentage cell viability as 
determined by PI exclusion assay. (b) Percentage cell viability as determined by trypan blue 
exclusion assay. 
 
 
 
4.8 mAb 84 Killing is Specific to Undifferentiated hESCs 
4.8.1 Cytotoxicity assay on differentiated hESCs 
Table 4.1 lists the binding specificity of mAb 84 to the various cell 
types. It was also observed that the binding of mAb 84 to hESCs was down-
regulated as the cells differentiate to 8 day old EBs. To determine if 
cytotoxicity of mAb 84 was specific to the undifferentiated phenotype, hESCs 
were induced to differentiate either by depriving the cultures of fibroblast 
growth factor 2 (FGF-2) or by EB formation. Differentiation was assessed 
based on the expression of the pluripotent marker, TRA-1-60 (Figure 4.9a). 
After culturing the hESCs in the absence of FGF-2 for 12 days, partial 
differentiation of hESCs was observed, with 49% of the cell population still 
expressing TRA-1-60 compared to the undifferentiated hESC culture where 
greater than 95% of the cell population expresses TRA-1-60. Differentiation of 
hESCs to EBs for 22 days yielded 99% differentiation.  
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 When cells from these 3 conditions were incubated with mAb 84, the 
efficiency of cell killing corresponded closely with the percentage of TRA-1-60 
positive cells (Figure 4.9b). For undifferentiated hESCs, only ~1% of cells 
remained viable after incubation with mAb 84. The viability increased to 69% 
and 99% for FGF-2 starved and EB cultures respectively concluding that the 
cytotoxicity of mAb 84 is indeed specific to undifferentiated hESCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Relationship between hESC pluripotency and killing efficiency by mAb 84. 
(a) Cells stained with anti-TRA-1-60 and detected with a FITC-conjugated anti-mouse 
antibody. The shaded histogram represents staining with the negative control and open 
histograms represent staining with anti-TRA-1-60 mAb. (b) Incubation with mAb 84 at 4oC for 
45 min. Subsequently, viability of the cells were analysed by PI exclusion assay on the flow 
cytometer. Gated region in the scatter plot represents the viable cell population. 
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4.8.2 Triple staining of hESCs and differentiated cells 
Using a direct approach to determine if the cytotoxicity of mAb 84 was 
specific only to the undifferentiated phenotype, we co-stained live hESCs and 
differentiating cells with mAb 84 and the pluripotent marker, TRA-1-60. At the 
same time, viability of the cells was analyzed via PI assay (Figure 4.10). 
Differentiation was achieved by culturing hESCs in the absence of FGF-2 for 
12 days.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 Triple staining of cells with mAb 84, TRA-1-60 and PI (a) Undifferentiated 
hESCs, (b) Differentiating cells cultured in the absence of FGF-2 for 12 days.  
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The population of double positive cells (84+/Tra+) was higher in the 
undifferentiated hESCs than the differentiated cells, 57% compared to 20%. 
These double positive cells also corresponded to cells with higher PI staining.  
This suggests that pluripotent cells were more susceptible to killing by mAb 
84.  Conversely, upon differentiation, the double negative population (84-/Tra-
) increased from 30% to 68% and these cells corresponded to cells with lower 
PI (viable population). Taken together, this data confirms that the mAb 84-
mediated is only specific to undifferentiated hESCs. 
 
4.9 mAb 84 Binds to O-linked Glycans on PODXL 
Loo et. al. have shown that the binding of antibody RAV12 to its 
antigen is associated with N-linked glycans [34]. As previously mentioned, 
PODXL is highly glycosylated sialomucin [74,75]. We proceeded to 
investigate if the binding of mAb 84 to PODXL is dependent on post-
translational modifications. In general, there are 2 kinds of glycosylation, 
namely; N-linked and O-linked glycosylation [82]. In their work, Loo et. al. 
utilized enzymes to deglycosylate the antigen and investigated the effect on 
antibody binding [34]. The common enzyme used to cleave N-glycans is 
peptide N-glycosidase (PNGase) F [34,83,84]. Due to the complexity of O-
linked glycosylation, several enzymes are utilized to cleave the various glycan 
residues. For example, sialidase cleaves the terminal sialic acid residues and 
endo-α-N-acetylgalactosaminidase (O-glycanase) is used to cleave the O-
glycans post sialidase treatment [34,84]. 
We first investigated if the binding of mAb 84 is associated with N-
linked glycans. After immuno-precipitation of PODXL by mAb 84, the eluate 
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was digested with PNGase F and probed with mAb 84 and commercially 
available anti-PODXL (Figure 4.11). From the Western blot analysis, the 
binding of mAb 84 was not lost after N-glycan removal with PNGase F. On the 
contrary, mAb-PODXL binding to PODXL is associated with N-linked glycans. 
 
 
   
 
 
 
 
 
 
 
Figure 4.11 Western blot analysis of immuno-precipitated PODXL post PNGase F 
treatment. Affinity purified PODXL from hESC lysate using PhyTip columns containing 
protein A resin and mAb 84 was treated with PNGase F and resolved on SDS-PAGE and 
subjected to Western blot. Lane 1: Lysate (control); Lane 2: IB with mAb 84; Lane3: IB with 
mAb to human PODXL (mAb-PODXL) and Lane 4: IB with pAb to human PODXL (pAb-
PODXL). 
 
 
 
Next, we investigated if the binding of mAb 84 was associated with O-
linked glycans. After immuno-precipitation of PODXL by mAb 84, the eluate 
was sequentially digested with sialidase, PNGase F and O-glycanase to 
remove terminal sialic acid residues, N-linked glycans and O-linked glycans 
respectively (Figure 4.12a). Samples were taken after each step of enzymatic 
digestion and probed with mAb 84 (Figure 4.12b). Binding of mAb 84 was only 
lost after removal of O-glycans. From this data, we concluded that mAb 84 
binds to O-linked glycans on PODXL.   
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Figure 4.12 Western blot analysis of immuno-precipitated PODXL post O-glycanase 
treatment. (a) Affinity purified PODXL from hESC lysate using PhyTip columns containing 
protein A resin and mAb 84 was treated sequentially with sialidase, PNGase F and O-
glycanase. Samples were taken from each step for western blot analysis. (b) Samples post 
enzymatic treatment were resolved on SDS-PAGE and subjected to Western blot. Lanes on 
the blot correspond to the samples after each enzymatic digestion step. Lane 1: IP-ed 
PODXL; Lane 2: Sialic acid removed; Lane3: Sialic acid and N-linked glycans removed; and 
Lane 4: Sialic acid, N-linked and O-linked glycans removed. 
 
 
 
 
4.10 mAb 84 is Cytotoxic to Induced Pluripotent Stem Cells 
Recently, the reprogramming of differentiated human somatic cells into 
a pluripotent state has generated enormous interest in the stem cell field. 
These non-pluripotent cells which are induced to express pluripotent genes, 
1 2 3 4 
Lane 
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are known as induced pluripotent stem (iPS) cells [66,84-86]. Potentially, iPS 
cells can overcome two important obstacles associated with the use of hESC: 
immune rejection after transplantation and ethical concerns regarding the use 
of human embryos [25,66,67]. In addition, iPS cells have been shown to be 
comparable to hESCs in morphology, pluripotent marker expression and 
differentiation potential, including teratoma formation [23,25,86]. Hence, we 
proceeded to investigate if mAb 84 is also cytotoxic to iPS cells.   
We carried out flow cytometry analysis on 2 iPS cells which were 
derived by Thomson et. al. [66,67]. The iPS cells were derived from fetal lung 
fibroblasts (IMR90) and neonatal foreskin fibroblasts transfected with the 
pluripotent genes OCT-4, SOX-2, NANOG and LIN-28. From Figure 4.13a, 
mAb 84 binds to both iPS cells (ESIMR90, ES4SKIN) but not to their parental 
fibroblasts (IMR90 and Foreskin), indicating that PODXL is up-regulated after 
reprogramming of the parental fibroblasts to iPS cells. In addition, mAb 84 is 
cytotoxic to both iPS cells but not the parental fibroblasts (Figure 4.13b).     
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Figure 4.13 Flow cytometry analysis of mAb 84 on iPS cells. (a) mAb 84 binds to both iPS 
cells but not to their parental fibroblasts. (b) mAb 84 is cytotoxic to both iPS cells but not to 
their parental fibroblasts. (▇) represents no treatment control and (▇) represents mAb 84-
treated cells. 
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4.11 Summary 
This chapter details the work carried out to characterize mAb 84 in its 
application to kill hESCs. This characterization work entitled “Selection 
Against Undifferentiated Human Embryonic Stem Cells by a Cytotoxic 
Antibody Recognizing Podocalyxin-Like Protein-1” has been published in the 
journal, Stem Cells (refer to APPENDIX A). 
We described a panel of antibodies that was raised against hESCs with 
the main objectives of identifying novel hESC surface markers that 
characterizes hESC populations and potentially using these mAbs to separate 
residual undifferentiated hESCs from differentiated cells. Uniquely, one of the 
clones, mAb 84, not only bound to hESCs but was also cytotoxic to the cells. 
By IP and MS analysis, the target antigen of mAb 84 was identified as 
PODXL. Human PODXL is localized on chromosome 7q32-q33 with an open 
reading frame that encodes for a protein of 528 amino acids [73,74]. The 
calculated molecular weight of PODXL is 54 kDa but the apparent molecular 
weight is approximately 160-165 kDa, due to extensive glycosylation [74,75]. 
The presence of PODXL on undifferentiated hESCs was also reported by 
Brandenberger et. al. [78]. In addition, Schopperle and DeWolf reported the 
presence of a Stem Cell PODXL (SC-PODXL) on pluripotent stem cells [79]. 
Functionally, PODXL has been reported to have diverse roles 
depending on the cell type. In podocytes, PODXL acts as an anti-adhesion 
molecule and maintains the filtration slits open between podocyte foot 
processes by charge repulsion [76,77]. In high endothelial venules, PODXL 
acts as an adhesion molecule binding to L-selectin and mediating the 
tethering and rolling of lymphocytes [72]. In breast and prostate cancers, 
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PODXL has been implicated as an indicator of tumor aggressiveness [23,87]. 
Hence, it would be interesting to investigate if mAb 84 binds and kills these 
cancer cells. 
Unlike other cytotoxic mAbs that may require either the activation of 
complement or hypercross-linking to induce cell death, mAb 84 mediated-
killing of hESCs was found to be independent of both mechanisms and also 
independent of temperature [32-34,80,81,88]. In addition, mAb 84 kills hESCs 
in a time and concentration dependent manner. We have also shown that 
mAb 84 binding and cytotoxicity is specific to undifferentiated hESCs and not 
differentiated cells. By enzymatic deglycosylation, results show that mAb 84 
binds to an O-linked glycan on PODXL. Extending our investigations to iPS 
cells, we observed that mAb 84 killing of iPS cells is as efficient as hESCs.  
Interestingly, PODXL, which is absent in the parental fibroblasts, is up-
regulated upon reprogramming making the cells susceptible to mAb84. 
In summary, the cytotoxic antibody, mAb 84, can be used as a cell 
surface marker for undifferentiated hESCs and iPS cells. In ESC therapy, 
mAb 84 may be applied as a death-inducing agent to kill and remove residual 
undifferentiated hESCs in differentiated populations, which potentially can 
form teratomas. The in vivo characterization of mAb 84 is presented in the 
next chapter.  
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CHAPTER 5 IN VIVO CHARACTERIZATION OF mAb 84 
 
5.1 Introduction 
The in vitro characterization of mAb 84 is presented in Chapter 4. We 
proceeded to investigate if treatment of hESCs in vitro with mAb 84 will 
eliminate its ability to form teratomas in vivo. This chapter details the animal 
studies performed with different starting cell populations and the consequence 
of mAb 84 treatment of them. In the first model, homogenous hESCs were 
treated with mAb 84 prior to transplantation into severe combined 
immunodeficiency (SCID) mice. We extended the model to mixed cell 
population where hESCs were differentiated into EBs or starved of FGF-2 
during culture for 12 days. The tumorigenic potential of these cell populations 
in vivo were then evaluated.  
 
5.2 Development of Teratoma Grading System 
Teratoma formation was monitored visually using a simple grading 
system that was confirmed by caliper measurements: grade 0 = no visible 
teratoma (6.32 mm average maximal hind leg diameter), grade 1 = teratoma 
just detectable (10.55 mm average), grade 2 = teratoma obvious (13.2 mm 
average), and grade 3 = teratoma impedes locomotion (14.52 mm average). 
Figure 5.1 shows the grading system and sizes of the teratomas formed in the 
SCID mice. 
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Figure 5.1 Grading system for teratoma formation. Teratomas are graded according to the 
size. 
 
 
 
5.3  In Vivo Model with Homogenous hESCs 
In the first animal model, we investigated whether hESCs treated with 
mAb 84 in vivo still had the potential to form teratomas after injection into 
SCID mice. Single-cell suspensions of hESCs were either treated with mAb 
84 or left untreated under identical conditions. When injected into the hind leg 
of SCID mice, all untreated transplants generated tumors (Figure 5.2), which 
started to form palpable and visible tumors between 6-9 weeks post-injection, 
and grew to full-sized tumors within 12 weeks. In contrast, when cells were 
treated with mAb 84 prior to injection, none of the injected animals developed 
tumors after 18-24 weeks.  
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Figure 5.2. Prevention of teratoma formation by mAb 84 in SCID mice. Single-cell 
suspension of hESCs (4 x 106 cells/animal) was incubated with mAb 84 at 4oC for 45 min and 
then injected into the right hind leg muscle of SCID mice (n = 4/group). Teratoma formation 
was evaluated with the grading method defined in section 5.2. 
 
 
 
This study was extended to evaluate other mAbs in our panel to 
determine the specificity and uniqueness of mAb 84 to eliminate teratoma 
formation in vivo. These mAbs include mAb 85, the isotype control which 
binds to PODXL but is not cytotoxic to hESC, mAb 14 (IgM) and mAb 8 (IgG) 
which binds to other cell surface markers on hESC. Consistently, hESCs 
treated with mAb 84 did not form teratomas in vivo, while hESCs treated with 
other mAbs, formed teratomas as early as week 7 post-injection (Figure 5.3). 
From these results, we concluded that the cytotoxic properties of mAb 84 on 
hESC is unique to the specific epitope recognized by the antibody on PODXL 
and not based only on binding to PODXL or to any surface antigens on hESC 
(mAb 84 vs mAb 85). Also, the cytotoxicity conferred is not dependent on the 
class of antibody. 
Control 
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hESC 
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Figure 5.3 Prevention of teratoma formation is unique to mAb 84. Work was extended to 
other antibodies in our panel, namely; mAb8, mAb 14 and mAb 85. 
 
 
5.4 In Vivo Model with Heterogenous Cell Population 
For the second animal model, we obtained mixed cell populations of 
differentiated and undifferentiated hESC either by differentiating hESCs into 5 
day EBs or culturing hESCs without FGF-2 for 12 days. The objective was 
was twofold: determine the percentage of PODXL positive cells remaining 
after differentiation and whether treatment of this cell mixture with mAb 84 
was able to eliminate residual undifferentiated hESCs and prevent or delay 
the formation of tumors in vivo.  
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5.4.1 In vivo model with Day 5 EBs 
When Day 5 EBs were trypsinized into single cells and stained with 
mAb 84, approximately 61% of PODXL +ve cells remained (Figure 5.4a). 
Although the expression of PODXL was down-regulated during differentiation 
to EBs, the residual PODXL +ve cell population remained susceptible to mAb 
84 killing as demonstrated by the decrease in cell viability (Figure 5.4b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Comparison of mAb 84 binding and killing of hESC and Day 5 EBs. (a) 
Binding of mAb 84 to undifferentiated hESCs and Day 5 EBs. A population of undifferentiated 
hESC (61%) remained in Day 5 EBs. (b) Relative cell viability after mAb 84 treatment. 
Viability of cells was calculated with respect to the control. (▇) represents untreated control, 
(▇) represents mAb 84-treated cells. The viability of cells in Day 5 EBs dropped to 64% after 
mAb 84 treatment, indicative of undifferentiated cell killing. 
 
 
 
The Day 5 EBs (both untreated and mAb 84 treated) were injected into 
SCID mice. However, no tumors were observed in either condition (after 24 
weeks). The absence of tumors even in the untreated condition could be due 
to the harsh cell harvesting protocol with trypsin. However this step was 
necessary in order to dissociate the aggregates into a single cell suspension 
prior to mAb treatment and injection. 
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5.4.2 In vivo Model with hESCs cultured without FGF-2  
The hESCs were cultured for 12 days in the absence of FGF-2. After 
differentiation, 66% of the cells were PODXL +ve and treatment with mAb 84 
killed 61% of the cells. This differentiation protocol enabled us to harvest the 
cells into single cell suspension via a less harsh method with PBS- rather than 
the use of trypsin which yielded low cell viability. Preliminary data from SCID 
mouse model showed that differentiating cells (both untreated and mAb-84 
treated) form tumors (Figure 5.5a). However, the development of tumor in the 
mAb 84-treated cells was much slower than that of the untreated (Figure 
5.5b). In the untreated controls, tumors formed within week 10 while in the 
mAb 84 treated cells, formation of tumors was delayed by 31/2 months. 
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Figure 5.5 SCID mouse model with cells cultured in the absence of FGF-2 for 12 days. 
SCID mice were injected with differentiating cells that were either not treated with any mAb or 
treated with mAb 84. (a) Preliminary data shows that untreated cells form larger tumors than 
mAb 84 treated cells.(b) Tumor formation was delayed by 31/2 months in mAb 84 treated cells 
compared to untreated cells. 
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5.5 Summary 
In the previous chapter, we demonstrated that undifferentiated hESCs 
can be eliminated following incubation with mAb 84 in vitro. Here, in vivo 
studies showed that injection of mAb 84-treated hESCs failed to form 
teratomas in a sensitive SCID mouse model. Extending our work to other 
mAbs in our panel, we showed that apart from mAb 84, treatment of hESCs 
with the other mAbs did not prevent teratomas and the onset was comparable 
to the untreated samples (as early as week 7 post-injection). We concluded 
that the binding and killing of hESCs by mAb 84 through PODXL is epitope 
specific and that the cytotoxicity is also not dependent on the class of 
antibody. 
To date, we have demonstrated that mAb 84 is able to prevent 
teratoma formation by undifferentiated hESCs. However, the ultimate goal is 
to utilize a differentiation model which will contain a heterogenous population 
of both differentiated and undifferentiated hESCs. The objective of utilizing the 
differentiation model experiments is two-fold. The first is to investigate the 
ability of mAb 84 to remove residual undifferentiated hESCs from a 
heterogeneous cell population after differentiation and prevent the formation 
of tumors in SCID mouse. The second is to demonstrate functional integration 
of the differentiated cells after treatment with mAb 84 
In addition to the mix cell model as described in section 5.4.2, we are 
currently investigating the application of mAb 84 in directed differentiation 
models. The differentiation model that we have adopted is based on the 
previously published protocol by Yang et. al. where hESCs were differentiated 
to chondrocytes in the presence of transforming growth factor-β3 [89]. This 
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differentiation protocol was shown to be robust and chondrogenic 
differentiation could be obtained with 2 hESC lines, H9 and HES-3. 
Preliminary work shows that undifferentiated hESC did not stain for Collagen-
2 (Col-2), a marker for chondrocytes, while hESC-derived chondrocytes 
stained positive for Col-2 (Figure 5.6). 
 
 
 
 
 
 
 
 
Figure 5.6 Staining for Col-2 in hESC-derived chondrocytes. (a) Undifferentiated hESC 
does not stain for Col-2. (b) hESC-derived chondrocytes express Col-2. 
 
 
However, the differentiation of hESCs to chondrocytes is not 100% 
efficient. In Figure 5.7b, a population of undifferentiated hESCs was still 
present after chondrogenic differentiation and these cells stained positive for 
both Oct-4 and PODXL (as stained with mAb 84). These residual 
undifferentiated hESC can potentially form teratomas in vivo. Currently, we 
are establishing the in vivo model. Due to time constraint, data for this 
experiment will not be presented. 
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Figure 5.7 Staining for PODXL and Oct-4 in hESC-derived chondrocytes. (a) 
Undifferentiated hESC stained positive for PODXL and Oct-4. (b) A population of cells within 
the hESC-derived chondrocytes stained for PODXL and Oct-4. 
 
 
 
 Preliminary work from the mixed cell model demonstrated that although 
mAb 84 was able to kill PODXL +ve cells, tumor formation still occurred but 
the onset was significantly delayed. This result suggests that the 
differentiating cells (PODXL -ve) may still posses the potential to form tumors. 
Currently, work is in progress to separate these PODXL –ve cells from the 
heterogenous population for in vivo studies to determine if this PODXL -ve 
population of cells is able to form tumors. 
Hence, for cell therapy utilizing hESC-derived products, we propose 
that several of the other hESC-specific mAbs in our panel can be used in 
combination with mAb 84 to ensure the complete removal of residual hESC. 
These mAbs, though not cytotoxic, can be conjugated to magnetic beads and 
used to isolate the hESCs from their differentiated progenies by magnetic cell 
separation technologies. 
Oct-4 
PODXL (a) Bright Field 
DAPI 
PODXL 
Oct-4 
(b) Bright Field 
DAPI 
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CHAPTER 6 ELUCIDATION OF DEATH MECHANISM OF 
mAb 84 
 
6.1 Introduction 
The previous two chapters detailed results of the in vitro and in vivo 
characterization of mAb 84 and its application to kill hESCs. In this chapter, 
the focus is to elucidate the mechanism responsible for hESC-killing by mAb 
84 after binding to PODXL. Broadly, cell death can be categorized into 2 
modes: apoptosis and oncosis [38,41,42,55]. Apoptosis is an organized and 
tightly controlled process. In most apoptosis models, cell death begins 12 to 
24 h after the initiation of a trigger, with the probable activation of caspases 
[41,47,48,55,90]. Other characteristics of apoptosis include cell shrinkage, 
chromatin condensation, plasma membrane phosphatidylserine 
externalization, budding of the plasma membrane and the fragmentation of 
chromosomal DNA [38,53-55]. Oncosis, on the other hand, is typically caused 
by ischemia or exposure to chemical toxins [42,55]. Its mechanism is based 
on failure of the ionic pumps of the plasma membrane, interference with ATP 
generation or increase in plasma membrane permeability [38,42,55]. Early 
manifestations consist of plasma membrane blebbing, dilation of the ER, 
mitochondrial swelling, and clumping of nuclear chromatin.  
 
6.2 Apoptosis Studies 
6.2.1 Rate of killing 
In most apoptosis models, cell death typically occurs within 12-24 h 
[41]. This suggests that the mode of mAb 84-mediated cell killing of hESCs is 
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unlikely through apoptosis. To demonstrate this difference in the rate of 
induced cell death, we performed a propidium iodide (PI) assay on mAb 84-
treated and apoptosis-induced hESC (Figure 6.1). After 45 min incubation of 
hESCs with mAb 84, the viability relative to non-treated control dropped 
drastically to 9%. The viability of hESCs incubated with the isotype control, 
mAb 85, remained comparable to the no treatment control. On the other hand, 
the relative viability of apoptotic cells dropped to about 76%, even though the 
PI assay was carried out 2 h after the induction of apoptosis. Hence, the rate 
of cell death via apoptosis is much slower compared to mAb 84-mediated cell 
death. 
 
 
 
 
 
 
 
 
 
Figure 6.1 Comparison of hESC viability between mAb 84-treated cells and apoptotic 
hESCs. Relative viability (%) was calculated using the ratio of the viability of hESCs after 
mAb treatment to the viability of cells that were not treated with any antibody (No treatment 
control). The graph shows the relative viability of hESCs incubated with mAb 84 (▇). Controls 
include cells incubated with isotype control, mAb 85 (▇) and apoptotic cells that were induced 
by UV irradiation and incubated for 2 h (▇). Viability was determined via PI stain on a flow 
cytometer.  
 
 
 
6.2.2 TUNEL assay 
This observation is further reiterated by 2 complementary biochemical 
assays for apoptosis. The first assay was to measure the extent of DNA 
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fragmentation via TUNEL assay [42,53,54].[43] From Figure 6.2, mAb 84-
treated cells did not exhibit significant elevation in the level of DNA 
fragmentation compared to the isotype control, mAb 85. On the contrary, 
apoptotic hESC exhibited a significant elevation in the level of DNA 
fragmentation.  
 
 
 
 
 
 
 
 
Figure 6.2 Degree of DNA fragmentation measured by TUNEL via flow cytometry. 
 
6.2.3 Caspase activation 
Next, we compared the activity of several caspases between mAb 84-
treated and apoptotic hESCs (Figure 6.3).  Results showed that the activity of 
caspases measured were at minimal basal levels for mAb 84-treated hESCs. 
In contrast, apoptosis-induced hESCs exhibited significantly higher caspase 
activities, in particular, caspases 2 and 3. The activities of these caspases 
were significantly reduced in cells that were incubated with ZVAD, an inhibitor 
to these capases. Hence, both results suggest that the mode of mAb 84-
mediated cell death is unlikely to be apoptosis. 
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Figure 6.3 Measured caspase activities. Error bars represent standard error of the mean of 
duplicate samples. 
 
6.2.4 Annexin staining 
Another characteristic of apoptosis is the exposure of the phospholipid, 
phosphatidylserine (PS), on the external surface of the cell. The detection of 
PS has been widely accepted as a hallmark of apoptosis and is detected by 
Annexin V [50,51,91-94].[95-99] In our experiments, surprisingly PS was 
detected by Annexin V in both apoptotic cells and mAb 84-treated cells 
(Figure 6.4 a and b). However, it is likely that the latter result is an artifact and 
not due to the exposure of PS on the external surface of the mAb 84-treated 
cells[55,56]. We speculate that because the membrane becomes permeable 
after mAb 84 treatment (increase in PI uptake), Annexin V is detecting 
intracellular PS instead. To validate this, hESCs were fixed, permeabilized 
and incubated with Annexin V (Figure 6.4c). Similar to mAb 84-treated 
hESCs, fixed and permeabilized hESCs had an elevated binding of annexin V 
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but to intracellular PS. Due to the mechanism which mAb 84 kills the cells, we 
are not able to utilize this assay. 
 
 
 
 
 
 
Figure 6.4 Detection of PS via annexin staining. (a) Non-apoptotic cells (green) versus 
apoptotic cells (purple). (b) mAb 84-treated cells (blue) versus mAb 85-treated cells (green). 
(c) Live cells (green) versus fixed and permeabiilzed cells (blue). 
 
 
 
6.3 Oncotic Studies 
6.3.1 mAb 84 induces plasma membrane damage  
Alternatively, we investigated oncosis as the probable mode of mAb 
84-mediated cell death. Oncosis is characterized by an increase in cell 
membrane permeability and altered membrane morphology due to damage to 
the plasma membrane [42,57-62].[47-50] The increase in membrane 
permeability of the cells can be assessed by the leakage of intracellular 
lactate dehydrogenase (LDH) and Na+ from the cells and entry of dextran 
beads into the cells [52,53,57-62,100-102]. 
 
6.3.1.1 Leakage of LDH out of cells 
 
LDH leakage has been used as a marker for increase membrane 
permeability during cell death [57-59,62]. Human ESCs were incubated for 45 
min either with mAb 84, the isotype control mAb 85 or untreated (No 
(a) (b) (c) 
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treatment control). Subsequently, the clarified supernatant was collected and 
assayed for LDH activity (Figure 6.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5 Measurement of LDH activity in the supernatant after treatment of hESC with 
antibodies. Cells were incubated with antibodies for 45 min and LDH activity measured. (□) 
represents sample at t = 0 min. (▇) represents untreated control, (▇) represents mAb 84-
treated cells, (▇) represents mAb 85-treated cells, (▇) represents total LDH (leaked LDH in 
the supernatant and LDH that remains in the cells). 
 
 
Interestingly, there were no significant differences in the LDH activity 
between the untreated control, mAb 84- and mAb 85-treated cells despite the 
increase in membrane permeability of mAb 84-treated hESCs compared to 
the controls. This was probably due to the high percentage of dead cells after 
harvesting with trypsin resulting in the elevated basal LDH levels into the 
supernatant. This consequently masked any changes to the LDH activity after 
incubating the hESCs with mAb 84. 
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6.3.1.2 Leakage of Na+ out of cells 
 
Alternatively, the increase in membrane permeability of the cells can be 
assessed by the leakage of intracellular Na+ from the cells [52,53,100-102]. 
The fluorescence level within the cells increased upon irreversible coupling of 
intracellular Na+ with a fluorescence dye (Figure 6.6). When these cells were 
treated with mAb 85, the fluorescence level remained as high as the non-
treated control. However, upon incubation with mAb 84, the fluorescence level 
within the cells decreased, suggesting the leakage of intracellular Na+ out of 
the cells as a result of increased membrane permeability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Coupling of intracellular Na+ with fluorescence dye. Fluorescence level of 
hESCs (loaded with fluorescence dye) after incubation with mAb 84 and mAb 85, compared 
with the ‘no treatment’ control. 
 
 
 
6.3.1.3 Entry of dextran beads into cells 
Studies have shown that plasma membrane damage in oncotic cells is 
caused by the formation of pores on the cell surface [36]. The sizes of these 
pores can be estimated with dextran beads of varying molecular weight 
[49,50,58,60,61].  From Figure 6.7, it was observed that both 3 and 2,000 kDa 
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dextran beads were able to diffuse into mAb 84-treated hESC, leading to an 
increase in fluorescence level comparable to fixed and permeabilized cells 
(positive control). This data suggest that the pores formed on the plasma 
membrane were greater than 2,000 kDa in size. In contrast, diffusion of 
dextran beads varying between 3 to 2,000 kDa into the cells for both controls 
(non-treated and mAb 85) were minimal (Figure 6.7). The percentage of cells 
that had higher fluorescence in the controls was attributed to the background 
of dead cells after cell harvest and incubation. In addition, based on our 
calculation, we estimated the diameter of the 2,000 kDa dextran beads to be 
approximately 20 m. This suggests that the size of the pores formed on the 
surface of the mAb 84-treated hESCs were larger than 20 m. 
 
 
 
 
 
 
 
 
 
Figure 6.7 Determination of pore size with 3kDa and 2,000 kDa dextran beads 
respectively. Cells were incubated with mAb 84, mAb 85, or not treated with any antibodies 
followed by fluorescent dextran beads. As a positive control, cells were fixed and 
permeabilized.  Increase in intracellular fluorescence is correlated with the entry of dextran 
beads into the cells. The population of cells with high fluorescence were gated and the 
percentages are represented in the graph. 
 
 
 
 
 
 
No treatment mAb 84 mAb 85 Fixed and  
Permeabilized 
No treatment mAb 84 mAb 85 Fixed and  
Permeabilized 
3 kDa Dextran Beads 20 kDa Dextran Beads 
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6.3.1.4 Visualization of cell surface with scanning electron microscopy 
(SEM) 
To further investigate the cytotoxic effects of mAb 84 on hESCs, we 
examined the cell surfaces for structural changes via SEM (Figure 6.8).  
Characteristically, pronounced clumping of hESCs after incubation with mAb 
84 was observed (Figure 6.8 B). Morphologically, these cells displayed a loss 
of surface microvilli, with the formation of membrane blebs and surface 
wrinkles. Most importantly, numerous pores were formed on the plasma 
membrane (Figure 6.8 E). The sizes of these pores were heterogeneous with 
diameters as large as 0.5 m (white arrows). This observation explains the 
entry of the 2,000 kDa dextran beads. In contrast, cells in both controls did not 
aggregate and preserved uniform morphology with normal cell surface 
structures (Figures 6.8 A, C, D and F). Our findings are similar to a previous 
study by Zhang et. al. and these results suggest that the mode of mAb 84-
mediated cell death is through oncosis [44]. 
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Figure 6.8 Observation of cell surface via SEM. (A-C) Magnifications are at x 2,000 (bar = 
10 m). (D-F) Magnifications are at x 10,000 (bar = 1 m). 
 
 
 
6.3.2 mAb 84-mediated oncosis involves changes in cytoskeleton 
proteins 
6.3.2.1 mAb 84-mediated oncosis causes the degradation of some 
cytoskeletal proteins 
Liu et. al. previously found that the increase in plasma membrane 
permeability of oncotic cells is closely correlated to modifications in structural 
proteins, namely, α-actinin, paxillin, talin and vinculin [62]. In particular, 
degradation of paxillin resulted in membrane permeability during oncosis [55].  
In mAb 84-mediated oncosis, significant degradation was observed with 
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cytoskeleton-associated proteins, α-actinin, paxillin and talin, compared to the 
controls (Figure 6.9). There was however no change in the levels of vinculin 
after mAb 84 treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9 Degradation of cytoskeleton-associated proteins. mAb 84-mediated oncosis 
leads to degradation of α-actinin, paxillin and talin. 
 
 
 
By immunocytochemistry and confocal microscopy, paxillin was found 
to localize at the periphery of the cell membrane after treatment with mAb 84 
(white arrows) as opposed to treatment with control mAb 85 where the 
staining of paxillin was diffuse within the cytoplasm (Figures 6.10 a and b 
respectively). Taken together, these results demonstrate a close association 
of the reorganization of cytoskeleton-associated α-actinin, paxillin and talin 
with mAb 84-mediated oncosis. 
No treatment mAb 84 mAb 85 
β-Actin 
α-Actinin 
Paxillin 
Talin 
Vinculin 
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Figure 6.10 Confocal microscopy of hESC after treatment with mAb 84 and mAb 85. (a) 
Co-localization of paxillin (green) at the periphery of the cell membrane with mAb 84 (red) as 
indicated by the white arrows. The nuclei are stained with DAPI (blue). Magnification is at x 
2520 (bar = 5 m). (b) Diffuse staining of paxillin (green) within the cells after treatment with 
mAb 85 (red). The nuclei are stained with DAPI (blue). Magnification is at x 2520 (bar = 5 
m). 
 
 
 
Takeda et. al. and Schmieder et. al. have shown that PODXL is 
connected to the actin filaments through the Na+/H+-exchanger regulatory 
factor 2 (NHERF2)/ezrin complex [76,103]. In a report by Lebart and 
Bentamin, the complex interaction between actin, numerous cytoskeleton 
proteins and integrins was mapped [104,105]. Piecing these data together, 
PODXL interacts with various cytoskeleton proteins and integrins. Hence, we 
proceeded to investigate if mAb 84-mediated oncosis causes the degradation 
of other cytoskeleton proteins apart from α-actinin, paxillin and talin. From 
Figure 6.11, mAb 84 treatment of cells causes the degradation of focal 
adhesion kinase NHERF -1 and -2, ezrin, α- and β- tubilin. However, integrin 
β-1 was not degraded during mAb 84-mediated oncosis. 
(a) (b) DAPI Paxillin 
mAb 84 
DAPI Paxillin 
mAb 85 
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Figure 6.11 Degradation of other cytoskeleton-associated proteins during mAb 84-
mediated oncosis. Integrin β-1 was not degraded after mAb 84 treatment. 
 
 
 
Confocal microscopy was also carried out to investigate if there was re-
organization of the actin filaments during mAb 84-mediated oncosis. From 
Figure 6.12, no apparent re-arrangement of the actin filaments was observed 
in mAb 84 treated cells compared to the controls. This was probably due to 
the fact that the cells had to be treated with the antibodies as a single cell 
suspension. The cells circularize and any morphology change in actin is not 
apparent. 
Integrin -1 
NHERF-1 
Actin 
Ezrin 
FAK 
NHERF-2 
α-Tubulin 
β-Tubulin 
No treatment mAb 84 mAb 85 
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Figure 6.12 Confocal microscopy to investigate changes in actin filament during mAb 
84-mediated oncosis. 
 
 
 
6.3.2.2 Degradation of cytoskeletal proteins during mAb 84-mediated 
oncosis occurs rapidly 
When we tracked the degradation of α-tubulin with time, we found that 
the protein degraded within 10 min post mAb 84 treatment (Figure 6.13). This 
result was consistent with the time course experiment whereby significant 
hESC was killed as fast as 15 min (Figure 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 Degradation of α-tubilin is time-dependent during mAb 84-mediated 
oncosis. The degradation of α-tubilin occurs as fast as 10min after the cells were treated with 
mAb 84. 
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6.3.2.3 Degradation of cytoskeletal proteins during mAb 84-mediated 
oncosis is not caused by calpains 
Increase in membrane permeability is a characteristic of oncosis. 
However, the mechanism underlying this increase in membrane permeability 
during oncosis is poorly understood [62]. Growing evidence indicates that the 
protease, calpain, plays a critical role in the process [55,62,106]. Calpain 
belongs to a family of 14 Ca2+-activated neutral cysteine proteases [55,107]. 
However, the biochemistry of most calpains and the specific roles of the 
different calpains in physiology and pathology remains to be determined. 
Various studies have identified a number of calpain substrates in cellular 
systems. These calpain substrates include numerous cytoskeleton proteins 
[63,107-111]. Studies also suggest that calpains mediate the increase in 
plasma membrane permeability and the progressive breakdown of the 
membrane during oncosis through the proteolysis of cytoskeletal and plasma 
membrane proteins [55,62,106].  
We proceeded to investigate if calpain is responsible for increase in 
membrane permeability and degradation of cytoskeleton proteins observed in 
mAb 84-mediated oncosis (Sections 6.3.1 and 6.3.2). Calpain inhibitors have 
been successfully used to demonstrate calpain involvement in several studies 
[55,62,65,106]. In these studies, the authors showed that they were able to 
prevent the hydrolysis of cytoskeletal proteins, minimize membrane 
permeability and significantly improve cell viability during oncosis when they 
treated the cells with calpain inhibitors prior to trigger of oncosis [62,106].  
Here, hESCs were pre-incubated for 24 h with an array of calpain inhibitors 
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before treatment with mAb 84. From Figure 6.14, it was observed that none of 
the calpain inhibitors were able to prevent mAb 84-mediated cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 6.14 An array of calpain inhibitors was tested to prevent mAb 84-mediated 
oncosis. Cells in culture were pre-incubated with the inhibitors for 24 h prior to mAb 84 
treatment. (▇) represents untreated control, (▇) represents mAb 84-treated cells. None of 
the inhibitors was able to inhibit mAb 84-mediated oncosis. 
 
 
 
6.3.3 mAb 84-mediated oncosis involves oligomerization of antigens 
We also hypothesized that the degradation of these cytoskeleton-
associated proteins increases the mobility of the cell surface proteins, thus 
permitting PODXL to oligomerize following binding to the pentameric mAb 84.  
This perturbation of the cell membrane consequently leads to pore formation 
on hESCs. This phenomenon of PODXL oligomerization was visualized via 
SEM following tagging of mAb 84 and mAb 85 with secondary antibodies 
conjugated to colloidal gold. From Figure 6.15, no non-specific binding of the 
secondary antibody to the cells was observed in the non-treated control. For 
mAb 84-treated cells, large clusters of antibodies were detected as opposed 
to mAb 85-treated cells, where the antibody binding was distributed 
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throughout the cells in small clusters. An important point to note was that the 
cells were sputtered with carbon, instead of gold, to allow the differentiation of 
the secondary gold particles from the cells for SEM visualization. However 
using this counter stain method, it was not possible to simultaneously 
visualize pore formation and antibody-antigen aggregation. Thus, the data in 
Figures 6.8 and 6.15 suggest that the oligomerization of antigens occurs 
following mAb 84 treatment on hESCs, consequently forming pores on the 
plasma membrane.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15 Aggregation of antigens upon incubation of hESCs with mAb 84. Antigen 
aggregation as visualized by SEM. Magnification is at x 10,000 (bar = 2 m). 
 
 
 
6.4 Summary 
In this chapter, we elucidated the death mechanism of mAb 84 killing. 
The work reported here was published in Stem Cells, entitled “mAb 84, a 
Cytotoxic Antibody that Kills Undifferentiated Human Embryonic Stem Cells 
via Oncosis” (refer to APPENDIX A). We showed that mAb 84 is unlikely 
inducing hESC killing via apoptosis based on TUNEL and caspase activity 
assays. Instead, from our observations, we concluded that cell death is 
mediated via a process similar to oncosis.  Many of our findings are consistent 
with previous work carried out by Zhang et. al. where an antibody, anti-
No treatment mAb 84 mAb 85 
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Porimin, kills Jurkat cells via a process similar to oncosis [36]. Both mAb 84 
and anti-Porimin bind to antigens that are highly glycosylated, with cell death 
observed as fast as 20 min. In addition, both antibodies mediate cell death 
that was preceded by rapid cell aggregation, pore formation on the plasma 
membrane, cell swelling and membrane blebbing. The similarities between 
anti-Porimin and mAb 84 are summarized in Table 6.1. 
Although oncosis and apoptosis are 2 different cell-death processes, 
the characteristics between apoptosis and oncosis are not distinct. One such 
characteristic is the exposure of the phospholipid, phosphatidylserine (PS), on 
the external surface of the cell. The detection of PS has been widely accepted 
as a hallmark of apoptosis and is detected by Annexin V [50,51,91-99]. 
However, Lecoeur et. al. demonstrated that the exposure of PS is not limited 
to apoptosis but is also associated with oncosis [56]. In our experiments, PS 
was also detected by Annexin V staining on the flow cytometer in mAb 84-
treated cells. However, this detection of PS was not due to its exposure on the 
external surface of the mAb 84-treated cells. Instead, the pores (> 2,000 kDa) 
formed on hESC after mAb 84 treatment were sufficiently large for Annexin V 
(~33 kDa) to enter the cells and bind to the intracellular PS [55,56,112-114]. 
Intracellular PS was also detected in healthy cells that were fixed and 
permeabilized to allow the entry of Annexin V into the cells. Hence, due to the 
unique mechanism of mAb 84-mediated cell killing, the use of Annexin as an 
absolute marker to demonstrate apoptosis is questionable. 
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Table 6.1 Similarities between anti-Porimin and mAb 84. 
 
Characteristic Anti-Porimin mAb 84 
   
Not apoptosis No DNA fragmentation/laddering 
No DNA fragmentation 
Low caspase activities 
   
Antigen - highly glycosylated 
Calculated MW ~ 21.5 kDa 
Apparent MW ~ 55-110 kDa 
Calculated MW ~ 55 kDa 
Apparent MW ~ 200 kDa 
   
Cell death Occurs ~ 20 min Occurs ~ 15-20 min 
   
Increase membrane 
permeability 
PI PI, Trypan blue, Na+ 
   
Aggregation of cells Yes Yes 
   
Pore formation Visualized through SEM Visualized through SEM 
   
 
 
 
Consistent with past work on oncosis, we also observed the 
degradation of cytoskeleton-associated proteins, such as α-actinin, paxillin 
and talin, and the degradation of these proteins was found to be time-
dependent [62]. Previous studies have identified the role of a calcium-
dependent protease, calpain, in the hydrolysis of these cytoskeleton-
associated proteins [55,62,63,104-110,115-117]. Interestingly, these calpain 
substrates can be linked to PODXL. It has been reported that PODXL 
complexes with erzin and Na+/H--exchanger regulatory factor (NHERF) which 
interacts with actin and these cytoskeleton-associated proteins [103,104,118-
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122]. However, we failed to elucidate the role of calpain in mAb 84-mediated 
oncosis. 
Putting our data together, a model is proposed to illustrate the events 
that occur in mAb 84-mediated oncosis of hESCs (Figure 6.16). When mAb 
84 binds to the highly glycosylated PODXL, it causes the degradation of 
cytoskeleton-associated proteins. Hydrolysis of these proteins increases the 
mobility of PODXL, resulting in the clustering of antigens on the cell surface 
due to crosslinking by the pentameric mAb 84.  Consequently, the 
oligomerization of the antigens results in the formation of pores on the plasma 
membrane.  To our knowledge, this is the first study on antibody-mediated 
oncosis which utilizes hESCs as a model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16 Proposed model for mAb 84-mediated oncosis. 
PODXL 
mAb 84 
 
Re-assembly of cytoskeleton-associated proteins 
• Permits movement of PODXLs 
• Aggregation of PODXL by mAb 84 
• Formation of Pores 
 
  
   
 95
CHAPTER 7 CONCLUSION AND FUTURE WORK 
 
7.1 Conclusion 
A panel of antibodies was raised against hESCs with the aim of 
identifying novel hESC surface markers, characterizing hESC populations and 
using these mAbs to separate residual undifferentiated hESCs from 
differentiated cells. One of the mAbs from this panel, mAb 84, not only binds 
to but also kills hESCs. In vitro characterization of mAb 84 found that: 
(1) mAb 84 specifically kills undifferentiated hESCs and not 
differentiated cells. 
(2) By IP and MS analysis, the antigen which mAb 84 binds to 
on hESCs was identified as podocalyxin-like protein-1 
precursor (PODXL). The protein is highly glycosylated with 
an apparent molecular weight of ~200 kDa. 
(3) mAb 84 mediated-killing of hESC is independent of 
complement and temperature. 
(4) mAb 84 mediated-killing of hESCs occurs rapidly. Based of 
PI exclusion assay, the cytotoxic effect of mAb 84 on hESCs 
was observed as quickly as 15 min after incubation with the 
viability dropping to 33%, with a further decrease in viability 
to 20% after 45 min.  
(5) Efficiency of mAb 84 mediated-killing of hESCs is dose 
dependent. In our experiments, when 2 x 105 cells was 
resuspended in 200 µl buffer,  more than 70% of cells was 
killed by 1ug of mAb 84. 
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(6) The binding of mAb 84 to PODXL is via O-linked glycans. 
(7) mAb 84 is also cytotoxic to iPS cells. 
From in vivo characterization of mAb 84, we demonstrated that the in 
vitro treatment of homogenous populations of hESCs with mAb 84 eliminated 
teratoma formation in SCID mouse models. Extending the work to other 
hESC-specific mAbs in our panel, we showed that only hESCs treated with 
mAb 84 did not form teratomas in vivo. Treatment with the other mAbs failed 
to prevent the onset of teratoma formation which occurred as early as 7 
weeks post-injection. From this, we concluded that the binding and killing of 
hESCs by mAb 84 is epitope specific and that the cytotoxicity is probably not 
dependent on the class of antibody. 
We also extended these animal model studies to a heterogenous 
population of undifferentiated hESCs and differentiated cells generated by 
spontaneously differentiating the cells in the absence of FGF-2 for 12 days. 
From this preliminary work, we found that although mAb 84 treatment failed to 
prevent the formation of teratomas in vivo, it was able to delay the onset of 
teratoma formation compared to the non-mAb84 treated control. We 
speculate that the differentiating cells may still possess the potential to form 
teratomas however this requires more detailed investigation. Currently, work 
is in progress to separate the PODXL –ve cells from the heterogenous 
population for in vivo studies to determine if the PODXL -ve cell population is 
able to form teratomas. For cell therapy utilizing hESC-derived products, we 
propose that several of the other hESC-specific mAbs in our panel can be 
used in combination with mAb 84 to ensure the complete removal of residual 
hESCs. These mAbs, though not cytotoxic, can be conjugated to magnetic 
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beads and used to isolate the hESCs from their differentiated progenies by 
magnetic cell separation technologies. 
We also elucidated the mechanism responsible for hESC killing 
following mAb 84 binding. It was determined that binding of mAb 84 induced 
oncosis in hESCs and a model was proposed to illustrate the series of events 
that occur. Following mAb 84 binding to the highly glycosylated PODXL, it 
causes the degradation of several cytoskeleton-associated proteins such as 
α-actinin, paxillin and talin. Hydrolysis of these proteins increases the mobility 
of PODXL, resulting in the aggregation of PODXL on the cell surface due to 
crosslinking by the pentameric mAb 84. Consequently, the oligomerization of 
the PODXL results in the formation of pores on the plasma membrane.  
This is the first study on antibody-mediated oncosis which utilizes 
hESCs as a model. The significance of these findings is that this antibody can 
be used to eliminate contaminating hESCs and iPS cells from the 
differentiated cell population prior to clinical applications because teratoma 
formation in vivo would severely compromise the success of the transplant. 
This “clean-up” step prior to transplantation will increase the safety of this 
procedure and alleviate concerns over the use of hESCs and iPS cells as the 
starting cell population for cell therapy.   
 
 
7.2 Future Work 
7.2.1 In vitro characterization of mAb 84 
For in vitro characterization of mAb 84, it would be interesting to 
investigate if mAb 84 binds and kills other cancer cells apart from the 
embryonal carcinoma cell line, NCCIT. It has been reported that the antigen 
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PODXL is found in breast and prostate cancers and has been implicated as 
an indicator of tumour aggressiveness [23,87]. 
 
7.2.2 In vivo characterization of mAb 84 
Based on our preliminary results, we have shown that mAb 84 is able 
to significantly delay the onset of tumor formation in heterogenous cell 
population where the cells were spontaneously differentiated in the absence 
of FGF-2 for 12 days. This result suggests that the differentiating cells 
(PODXL -ve) may still possess the potential to form tumors. Currently, work is 
in progress to separate the PODXL –ve cells from the heterogenous 
population for in vivo studies to determine if these cells are able to form 
teratomas. 
Studies are also being carried out with directed differentiated model. 
The differentiation model that we have adopted is based on the previously 
published protocol by Yang et. al. where hESCs were differentiated to 
chondrocytes in the presence of transforming growth factor-β3 [89]. The 
objective of these experiments is two-fold. The first is to investigate the ability 
of mAb 84 to remove residual undifferentiated hESC from a heterogeneous 
cell population after differentiation and prevent the formation of tumors in 
SCID mouse. The second is to demonstrate functional integration of the 
differentiated cells after treatment with mAb 84 at the injury site.  
Preliminary work on the hESC-derived chondrocytes showed that 
undifferentiated hESCs did not stain for Collagen-2 (Col-2), a marker for 
chondrocytes, while the hESC-derived chondrocytes stained positive for Col-
2. However, the differentiation of hESCs to chondrocytes is not 100% 
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efficient. A population of undifferentiated hESCs was still present after 
chondrogenic differentiation and these cells stained positive for both Oct-4 
and PODXL. These residual undifferentiated hESCs can potentially form 
tumorss in vivo. Currently, we are establishing the in vivo model for the hESC-
derived chodrocytes. In addition to chondrogenic differentiation, other directed 
differentiation protocols may also be explored, e.g. cardiomyocytes. This will 
enable us to demonstrate the generic utility of mAb 84 to eliminate 
contaminating hESCs from different cell populations and more importantly, 
demonstrate that the differentiated cells remain functional after treatment with 
mAb 84. 
In addition to hESCs, we would like to expand the in vivo work to iPS 
cells since patient-specific iPS cells are also a valuable source of cells for 
therapy and drug screening. The in vivo models for iPS cells would be similar 
to that for hESCs, namely; homogenous iPS cells, heterogeneous mix cell 
population and differentiation models with iPS cells. 
 
7.2.3 Elucidation of death mechanism of mAb 84 
A model has been proposed to describe the mechanism of mAb 84-
induced oncosis. As mAb 84 kills hESCs rapidly, we would like to investigate 
the possible role of calcium ions as second messengers upon antibody 
binding to PODXL [123]. Studies have also shown that Ca2+ is involved in 
many cell signaling processes including cell death [123,124]. Recently, it was 
also suggested that F-actin and actin-binding proteins may modulate the 
release of Ca2+ [125,126]. As described, PODXL complexes with erzin and 
Na+/H--exchanger regulatory factor (NHERF) which interacts with actin [103]. 
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Hence, it will be interesting to investigate any perturbation in Ca2+ 
concentration upon mAb 84 binding to PODXL which ultimately leads to pore 
formation on the plasma membrane. Such perturbation in Ca2+ concentration 
can be studied via patch clamp [127,128]. Currently, preliminary studies are 
being carried out in collaboration with Prof Soong (Physiology NUS) 
leveraging on his expertise in patch clamping. 
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ABBREVIATIONS 
 
 
 
APC  Allophycocyanin 
ATP  Adenosine-5'-triphosphate  
BSA  Bovine serum albumin 
CAD  Caspase-activated DNAse 
CM  Condition media 
CO2  Carbon dioxide 
Col-2  Collagen 2 
DMEM  Dulbecco's modiﬁed Eagle's medium  
DNA  Deoxyribonucleic acid  
DTT  Dithiothreitol  
dUTPs  Deoxynucleotide triphosphates  
EB  Embryoid bodies 
EC  Embryonal carcinoma 
EDTA  Ethylenediaminetetraacetic acid  
ESI  ES Cell International 
EST  Expressed sequence tag  
Fab  Fragment, antigen binding 
FAK  Focal adhesion kinase 
FGF-2  Fibroblast growth factor-2 
FITC  Fluorescein isothiocyanate 
GAH  Goat-anti-human 
GAM  Goat-anti-mouse  
HAT  Hypoxanthine-aminopterin-thymidine 
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hESC  Human embryonic stem cell 
HPC  Hematopoietic progenitor cells 
HRP  Horseradish peroxidase 
IB  Immuno-blot 
iCAD  Inhibitor of caspase activated DNAse 
IDA  Information dependent acquisition 
IgG  Immunoglobin G 
IgM  Immunoglobin M 
IP  Immuno-precipitation 
iPS cells  Induced pluripotent stem cells 
KO  Knockout 
LDH  Lactate dehydrogenase 
mAb  Monoclonal antibody 
MDCK  Madin-darby canine kidney 
MS  Mass spectrometry 
MW  Molecular weight 
NaH2PO4  Sodium dihydrogen phosphate 
NEAA  Non-esential amino acids 
NHERF  Na+/H+ exchanger regulatory factor 
pAb  Polyclonal antibody 
PBS  Phosphate buffer saline 
PE  Phycoerythrin 
PI  Propidium iodide 
PLL  Poly-L-lysine 
PODXL  Podocalyxin 
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PS  Phosphotidylserine 
PVDF  Polyvinylidene fluoride 
RPT  Renal proximal tubules 
S/N  Supernatant 
SCID  Severe combined immunodeficiency 
SC-PODXL  Stem cell podocalyxin 
SEM  Scanning electron microscopy 
SSEA-3  Stage-specific embryonic antigen-3 
SSEA-4  Stage-specific embryonic antigen-4 
TDT  Terminal deoxynucleotidyl transferase 
TGFB3  Transforming growth factor beta-3  
TRA-1-60  Tumour rejection antigen-1-60  
TRA-1-61  Tumour rejection antigen-1-81 
TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end 
labeling  
UV  Ultra-violet 
ZVAD  Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl] 
ΔE-MEF   Immortalized mouse embryonic fibroblasts 
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